var title_f17_12_17600="Typical molluscum bumps";
var content_f17_12_17600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical molluscum bumps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 262px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the pearly appearance and the dimple in the center of the bumps.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Overview of Molluscum Contagiosum. file://www.cdc.gov/ncidod/dvrd/molluscum/overview.htm. Accessed May 30, 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17600=[""].join("\n");
var outline_f17_12_17600=null;
var title_f17_12_17601="Patient information: Heart failure (The Basics)";
var content_f17_12_17601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Heart failure (The Basics)",
"  </div>",
"  <a href=\"./authors-and-editors/patient-information\">",
"   Written by the doctors and editors at UpToDate",
"  </a>",
"  <br/>",
"  <br/>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 23, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H737866103\">",
"    <span class=\"h1\">",
"     What is heart failure?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure is a condition in which the heart does not pump well. This causes the heart to lag behind in its job of moving blood throughout the body. As a result, fluid backs up in the body, and the organs in the body do not get as much blood as they need. This can lead to symptoms, such as swelling, trouble breathing, and feeling tired.",
"   </p>",
"   <p>",
"    If you have heart failure, your heart has not actually &ldquo;failed&rdquo; or stopped beating. It just isn&rsquo;t working as well as it should.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H737866110\">",
"    <span class=\"h1\">",
"     What are the symptoms of heart failure?",
"    </span>",
"    &nbsp;&mdash;&nbsp;If your heart does not pump well, at first you might have no symptoms. But as the condition gets worse, it can cause:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tiredness or weakness, or make you feel lightheaded or dizzy",
"     </li>",
"     <li>",
"      Trouble breathing, which might lead you to be less active or to need extra pillows at night to sleep",
"     </li>",
"     <li>",
"      A racing heartbeat, even while resting",
"     </li>",
"     <li>",
"      Swelling in your feet, ankles, and legs (",
"      <a class=\"graphic graphic_picture graphicRef61706 \" href=\"UTD.htm?15/43/16050\">",
"       picture 1",
"      </a>",
"      ) or in your belly",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H737866117\">",
"    <span class=\"h1\">",
"     Is there a test for heart failure?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse thinks you might have heart failure, he or she might order some of the following tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       A chest X-ray &ndash;",
"      </strong>",
"      A chest X-ray shows if there is fluid in the lungs. It also shows the general shape of the heart and large blood vessels in the chest.",
"     </li>",
"     <li>",
"      <strong>",
"       An electrocardiogram (ECG or EKG)",
"      </strong>",
"      &ndash; This test measures the electrical activity in your heart. It can show whether you have an abnormal heartbeat or had a heart attack in the past. These are some of the things that can cause heart failure.",
"     </li>",
"     <li>",
"      <strong>",
"       An echocardiogram &ndash;",
"      </strong>",
"      This test uses sound waves to create a picture of your heart as it beats. It shows the size of the heart chambers, how well the heart is pumping, and how well the heart valves are working.",
"     </li>",
"     <li>",
"      <strong>",
"       A stress test",
"      </strong>",
"      &ndash; During a stress test, you might be asked to run or walk on a treadmill while you have an ECG or other heart tests. Physical activity makes the heart pump harder and increases the heart&rsquo;s need for blood. This test helps doctors see if the heart is getting enough blood when it is under stress. If you cannot walk or run, you might instead get a medicine to stress your heart.",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiac catheterization",
"      </strong>",
"      &ndash; Cardiac (heart) catheterization is also known as cardiac &ldquo;cath&rdquo; or coronary angiography. During this test, the doctor inserts a thin tube into a large artery in your leg and threads it up to your heart. Then the doctor injects a dye that shows up on X-ray pictures. The pictures can show whether any of the arteries in your heart are narrowed or blocked.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H737866124\">",
"    <span class=\"h1\">",
"     What can I do on my own to protect my heart?",
"    </span>",
"    &nbsp;&mdash;&nbsp;If you do the following things, you will feel better and reduce the chances that you will need to go to the hospital:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Take your medicines every day, even if you feel well",
"      </strong>",
"      &ndash; The medicines your doctor prescribes can help you feel better and live longer. But they will work only if you take them every day.",
"     </li>",
"     <li>",
"      <strong>",
"       Watch for changes in your symptoms and follow an action plan",
"      </strong>",
"      &ndash; An action plan is a list of instructions on what to do if your symptoms change. To use an action plan, you must watch your symptoms closely and weigh yourself every day (see next bullet). If your symptoms get worse or if you gain weight suddenly, you must take action (",
"      <a class=\"graphic graphic_figure graphicRef72459 \" href=\"UTD.htm?19/63/20474\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef75501 \" href=\"UTD.htm?31/48/32522\">",
"       figure 2",
"      </a>",
"      ). Keep your action plan somewhere handy, such as on your refrigerator, so that you can always check it to see what you should do.",
"     </li>",
"     <li>",
"      <strong>",
"       Call your doctor or nurse if you gain weight suddenly",
"      </strong>",
"      &ndash; Weigh yourself every morning after you urinate but before you eat breakfast. Wear roughly the same amount of clothing every time. And make sure to write down your weight every day on a calendar. Call your doctor or nurse if your weight goes up by 2 or more pounds (1 kilogram) in one day, or 4 or more pounds (2 kilograms) in 1 week. When you have heart failure, sudden weight gain is a sign that your body could be holding on to too much fluid. You might need a change in your medicines.",
"     </li>",
"     <li>",
"      <strong>",
"       Cut down on salt",
"      </strong>",
"      &ndash; Try not to add salt at the table or when you cook. Also, avoid foods that come in boxes and cans, unless their labels say they are low in sodium (",
"      <a class=\"graphic graphic_table graphicRef61514 \" href=\"UTD.htm?1/41/1691\">",
"       table 1",
"      </a>",
"      ). The best choices for food are fresh or fresh frozen foods, and foods you prepare yourself (",
"      <a class=\"graphic graphic_table graphicRef74448 \" href=\"UTD.htm?1/55/1916\">",
"       table 2",
"      </a>",
"      ). Your doctor might also tell you to limit the amount of fluids you drink.",
"     </li>",
"     <li>",
"      <strong>",
"       Lose weight, if you are overweight",
"      </strong>",
"      &ndash; If you are overweight, your heart has to work extra hard to keep up with your body&rsquo;s needs.",
"     </li>",
"     <li>",
"      <strong>",
"       Stop smoking",
"      </strong>",
"      &ndash; Smoking worsens heart failure and increases the chance that you will have a heart attack or die.",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Limit alcohol",
"      </strong>",
"      &ndash; If you are a woman, do not have more than 1 drink a day. If you are a man, do not have more than 2 (",
"      <a class=\"graphic graphic_figure graphicRef56818 \" href=\"UTD.htm?20/18/20778\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Be active",
"      </strong>",
"      &ndash; Ask your doctor what activities are safe for you. Your doctor will let you know if activities such as walking or biking on most days of the week can help reduce your symptoms. But do not exercise if your symptoms are bothering you a lot.",
"     </li>",
"     <li>",
"      <strong>",
"       Check with your doctor before taking any new medicines or supplements",
"      </strong>",
"      &ndash; Some over-the counter and prescription medicines, &ldquo;natural&rdquo; remedies, and supplements are not good for people with heart failure. For example, medicines such as ibuprofen (sold as Advil&reg; or Motrin&reg;) and naproxen (sold as Aleve&reg;) can make heart failure worse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H737866131\">",
"    <span class=\"h1\">",
"     How is heart failure treated?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many treatments for heart failure, but medicines are a key part of controlling the condition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Take your medicines every day as directed. They can reduce the chances that you will need to go to the hospital, have a heart attack, or die. They can also reduce or get rid of your symptoms. That&rsquo;s why they are so important.",
"     </li>",
"     <li>",
"      Tell your doctor if you can&rsquo;t afford your medicines. He or she might have ways to reduce the cost of your medicines.",
"     </li>",
"     <li>",
"      Tell your doctor if your medicines cause side effects or other problems. Your doctor might be able to switch to another medicine or lower your dose so that you do not have that problem.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other treatments for heart failure include devices to help the heart pump with more force or to beat at the right rhythm, and surgery to improve blood flow to the heart or replace the heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H737866138\">",
"    <span class=\"h1\">",
"     More on this topic",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36499?source=see_link\">",
"     Patient information: Medicines for heart failure (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"     Patient information: Coronary heart disease (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=see_link\">",
"     Patient information: Chest pain (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"     Patient information: High blood pressure in adults (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=see_link\">",
"     Patient information: High cholesterol (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=see_link\">",
"     Patient information: Atrial fibrillation (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"     Patient information: Echocardiogram (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"     Patient information: ECG and stress test (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=see_link\">",
"     Patient information: Nuclear heart testing (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=see_link\">",
"     Patient information: What can go wrong after a heart attack? (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=see_link\">",
"     Patient information: Heart failure and atrial fibrillation (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=see_link\">",
"     Patient information: Cardiac catheterization (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?11/4/11331?source=see_link\">",
"     Patient information: When your lungs fill with fluid (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13956?source=see_link\">",
"     Patient information: Diastolic heart failure (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7684?source=see_link\">",
"     Patient information: Systolic heart failure (The Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"     Patient information: Heart failure (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"     Patient information: Heart attack (Beyond the Basics)",
"    </a>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15655 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-41.78.124.10-7353626C42-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17601=[""].join("\n");
var outline_f17_12_17601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H737866103\">",
"      What is heart failure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H737866110\">",
"      What are the symptoms of heart failure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H737866117\">",
"      Is there a test for heart failure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H737866124\">",
"      What can I do on my own to protect my heart?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H737866131\">",
"      How is heart failure treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H737866138\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   GRAPHICS",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     FIGURES",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/63/20474\" title=\"figure 1\">",
"      Heart failure action plan - page 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/48/32522\" title=\"figure 2\">",
"      Heart failure action plan - page 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/18/20778\" title=\"figure 3\">",
"      Standard alcoholic drink PI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     PICTURES",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/43/16050\" title=\"picture 1\">",
"      Pitting edema PI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     TABLES",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/41/1691\" title=\"table 1\">",
"      Sodium terms PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/55/1916\" title=\"table 2\">",
"      High low sodium foods PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=related_link\">",
"      Patient information: Atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=related_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13956?source=related_link\">",
"      Patient information: Diastolic heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=related_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36499?source=related_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=related_link\">",
"      Patient information: Nuclear heart testing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7684?source=related_link\">",
"      Patient information: Systolic heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=related_link\">",
"      Patient information: What can go wrong after a heart attack? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/4/11331?source=related_link\">",
"      Patient information: When your lungs fill with fluid (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_12_17602="Sequestration CXR III";
var content_f17_12_17602=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralobar sequestration right lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a mass at the right base, which obscures the right hemidiaphragm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17602=[""].join("\n");
var outline_f17_12_17602=null;
var title_f17_12_17603="Low Dye foot taping";
var content_f17_12_17603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Foot taping for plantar fasciitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A technique for taping the foot to treat plantar fasciitis is illustrated. The four panels show the technique from left to right. Panel 1:&nbsp;A strip of adhesive tape (the metatarsal strip) is applied in a circumferential fashion at the level of the metatarsal heads. Panel 2:&nbsp;A strip of tape is started at the lateral aspect of the plantar surface of the metatarsal strip, is applied diagonally across the sole, around the heel, along the lateral border of the foot, and ends on the metatarsal strip. Panels 3 and 4: The third and fourth strips are started at the lateral aspect of the metatarsal strip, are carried around the heel, and end on the metatarsal strip near the base of the great toe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17603=[""].join("\n");
var outline_f17_12_17603=null;
var title_f17_12_17604="RML atelectasis Lateral";
var content_f17_12_17604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right middle lobe atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view of the chest in the same patient. The minor and major fissures are parallel to each other (arrows), and the atelectatic lobe can be seen as a band of opacity between the fissures projecting over the cardiac silhouette.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lateral chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17604=[""].join("\n");
var outline_f17_12_17604=null;
var title_f17_12_17605="Cromolyn sodium (systemic therapy and oral inhalation): Drug information";
var content_f17_12_17605=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cromolyn sodium (systemic therapy and oral inhalation): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/53/29524?source=see_link\">",
"    see \"Cromolyn sodium (systemic therapy and oral inhalation): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/63/28660?source=see_link\">",
"    see \"Cromolyn sodium (systemic therapy and oral inhalation): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8012087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrocrom&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8012088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nalcrom&reg;;",
"     </li>",
"     <li>",
"      Nu-Cromolyn;",
"     </li>",
"     <li>",
"      PMS-Sodium Cromoglycate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8012247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Mast Cell Stabilizer",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8012189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Asthma:",
"     </b>",
"     For chronic control of asthma, taper frequency to the lowest effective dose (ie, 4 times/day to 3 times/day to twice daily).",
"     <b>",
"      Note:",
"     </b>",
"     Not effective for immediate relief of symptoms in acute asthmatic attacks; must be used at regular intervals for 2-4 weeks to be effective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nebulization solution:",
"     </i>",
"     Initial: 20 mg 4 times/day; usual dose: 20 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of bronchospasm (allergen- or exercise-induced):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Administer 10-15 minutes prior to exercise or allergen exposure but no longer than 1 hour before:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nebulization solution:",
"     </i>",
"     Single dose of 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mastocytosis:",
"     </b>",
"     Oral: 200 mg 4 times/day; given",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     hour prior to meals and at bedtime. If control of symptoms is not seen within 2-3 weeks, dose may be increased to a maximum 40 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Food allergy (unlabeled use), inflammatory bowel disease (unlabeled use):",
"     </b>",
"     Oral: Initial dose: 200 mg 4 times/day; may double the dose if effect is not satisfactory within 2-3 weeks; up to 400 mg 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8012188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/63/28660?source=see_link\">",
"      see \"Cromolyn sodium (systemic therapy and oral inhalation): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma:",
"     </b>",
"     inhalation: For chronic control of asthma, taper frequency to the lowest effective dose (ie, 4 times/day to 3 times/day to twice daily):",
"     <b>",
"      Note:",
"     </b>",
"     Not effective for immediate relief of symptoms in acute asthmatic attacks; must be used at regular intervals for 2-4 weeks to be effective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nebulization solution:",
"     </i>",
"     Children &gt;2 years: Initial: 20 mg 4 times/day; usual dose: 20 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of allergen- or exercise-induced bronchospasm:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Administer 10-15 minutes prior to exercise or allergen exposure but no longer than 1 hour before:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nebulization solution:",
"     </i>",
"     Children &gt;2 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Systemic mastocytosis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-12 years: 100 mg 4 times/day; not to exceed 40 mg/kg/day; given",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     hour prior to meals and at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Food allergy (unlabeled use), inflammatory bowel disease (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;2 years: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-12 years: Initial dose: 100 mg 4 times/day; may double the dose if effect is not satisfactory within 2-3 weeks; not to exceed 40 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Once desired effect is achieved, dose may be tapered to lowest effective dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8012190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8012191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific guidelines not available; consider lower dose of oral product.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8012192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific guidelines not available; consider lower dose of oral product.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8012240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization, as sodium: 20 mg/2 mL (60s, 120s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sodium [concentrate, preservative free]: 100 mg/5 mL (96s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrocrom&reg;: 100 mg/5 mL (96s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8012090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8012224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral solution: Open ampul and squeeze contents into glass of water; stir well; administer at least 30 minutes before meals and at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8012177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nebulizer solution is",
"     <b>",
"      compatible",
"     </b>",
"     with metaproterenol sulfate, isoproterenol hydrochloride, 0.25% isoetharine hydrochloride, epinephrine hydrochloride, terbutaline sulfate, and 20% acetylcysteine solution for at least 1 hour after their admixture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8012091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation: May be used as an adjunct in the prophylaxis of allergic disorders, including asthma; prevention of exercise-induced bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Systemic mastocytosis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8012092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Food allergy, treatment of inflammatory bowel disease",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8012118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angioedema, chest pain, edema, flushing, palpitation, premature ventricular contractions, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, behavior changes, convulsions, depression, dizziness, fatigue, hallucinations, headache, irritability, insomnia, lethargy, migraine, nervousness, hypoesthesia, postprandial lightheadedness, psychosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, photosensitivity, pruritus, purpura, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, dysphagia, esophagospasm, flatulence, glossitis, nausea, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia, pancytopenia, polycythemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver function test abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, leg stiffness, leg weakness, myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8012114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cromolyn or any component of the formulation; acute asthma attacks",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8012115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: Severe anaphylactic reactions may occur rarely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiac arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral: Use with caution in patients with hepatic or renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Prophylactic drug with no benefit for acute situations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Caution should be used when withdrawing the drug or tapering the dose as symptoms may reoccur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8012170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8012109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8012110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. No data available on whether cromolyn crosses the placenta or clinical effects on the fetus. Available evidence suggests safe use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8012112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8012113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data available on whether cromolyn enters into breast milk or clinical effects on the infant. Use of cromolyn is not considered a contraindication to breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8012193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Should be taken at least 30 minutes before meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8012242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Cromolyn Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (5 mL): $6.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Gastrocrom Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (5 mL): $7.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (Cromolyn Sodium Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/2 mL (2 mL): $1.92",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8012228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic pulmonary function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8012178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevents the mast cell release of histamine, leukotrienes, and slow-reacting substance of anaphylaxis by inhibiting degranulation after contact with antigens",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8012180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset: Response to treatment: Oral: May occur within 2-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation: ~8% reaches lungs upon inhalation; well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: &lt;1% of dose absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 80-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Inhalation: ~15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces (equal amounts as unchanged drug); exhaled gases (small amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ahmad S, &ldquo;Cromolyn Sodium and Anaphylaxis,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1983, 99:882.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hargreaves MR and Benson MK, &ldquo;Inhaled Sodium Cromoglycate in Angiotensin-Converting Enzyme Inhibitor Cough,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 345(8941):13-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/12/17605/abstract-text/7799699/pubmed\" id=\"7799699\" target=\"_blank\">",
"        7799699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Slater EF, &ldquo;Cardiac Tamponade and Peripheral Eosinophilia in a Patient Receiving Cromolyn Sodium,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1978, 73:838.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walter SR, Evans ME, Richard AJ, et al, &ldquo;The Fate of Disodium Cromoglycate in Man,&rdquo;",
"      <i>",
"       J Pharm Pharmacol",
"      </i>",
"      , 1972, 24:525-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/12/17605/abstract-text/4403844/pubmed\" id=\"4403844\" target=\"_blank\">",
"        4403844",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9090 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-BD74261493-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17605=[""].join("\n");
var outline_f17_12_17605=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012087\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012088\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012247\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012189\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012188\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012190\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012191\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012192\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012240\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012090\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012224\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012177\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012091\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012092\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012118\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012114\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012115\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299102\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012170\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012109\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012110\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012112\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012113\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012193\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012242\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012228\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012178\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012180\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9090\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9090|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/27/23987?source=related_link\">",
"      Cromolyn sodium (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/12/197?source=related_link\">",
"      Cromolyn sodium (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/24/35202?source=related_link\">",
"      Cromolyn sodium (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/3/28723?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/46/17124?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/45/19154?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/53/29524?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/63/28660?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_12_17606="Paroxetine: Patient drug information";
var content_f17_12_17606=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Paroxetine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     see \"Paroxetine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18361?source=see_link\">",
"     see \"Paroxetine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Paxil CR&reg;;",
"     </li>",
"     <li>",
"      Paxil&reg;;",
"     </li>",
"     <li>",
"      Pexeva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Paroxetine&reg;;",
"     </li>",
"     <li>",
"      CO Paroxetine;",
"     </li>",
"     <li>",
"      Dom-Paroxetine;",
"     </li>",
"     <li>",
"      Mylan-Paroxetine;",
"     </li>",
"     <li>",
"      Novo-Paroxetine;",
"     </li>",
"     <li>",
"      Paxil CR&reg;;",
"     </li>",
"     <li>",
"      Paxil&reg;;",
"     </li>",
"     <li>",
"      PHL-Paroxetine;",
"     </li>",
"     <li>",
"      PMS-Paroxetine;",
"     </li>",
"     <li>",
"      ratio-Paroxetine;",
"     </li>",
"     <li>",
"      Riva-Paroxetine;",
"     </li>",
"     <li>",
"      Sandoz-Paroxetine;",
"     </li>",
"     <li>",
"      Teva-Paroxetine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3671560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk to your doctor about using this drug while you are pregnant or if you are planning on getting pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691994",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat obsessive-compulsive problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat panic attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat social anxiety problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat post-traumatic stress.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat mood problems caused by monthly periods.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hot flashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702684",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to paroxetine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Linezolid or methylene blue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697339",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures or are on seizure drugs, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any natural products, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the morning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10950 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17606=[""].join("\n");
var outline_f17_12_17606=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206594\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206595\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020963\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020965\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020964\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020969\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020970\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020972\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020967\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020968\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020973\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020974\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=related_link\">",
"      Paroxetine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18361?source=related_link\">",
"      Paroxetine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_12_17607="Evaluation of the red eye";
var content_f17_12_17607=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the red eye",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/12/17607/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17607/contributors\">",
"     Deborah S Jacobs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/12/17607/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17607/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/12/17607/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17607/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/12/17607/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A \"red eye\" is a common presenting complaint. Some patients with red eyes need urgent ophthalmic referral and treatment, although the vast majority can be treated by the primary care clinician. There are little epidemiologic data on the red eye, nor are there evidence-based data to guide us in the management of these patients. Conjunctivitis (allergic or viral) is probably the most common cause of red eye in the community setting, but a number of more serious conditions can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17607/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will present an approach for distinguishing patients with red eye who must be referred to an ophthalmologist, such as those with angle-closure glaucoma, from patients who can be managed by the primary care clinician, such as those with allergic conjunctivitis (",
"    <a class=\"graphic graphic_table graphicRef75654 \" href=\"UTD.htm?2/48/2827\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56779 \" href=\"UTD.htm?9/26/9643\">",
"     table 2",
"    </a>",
"    ). Some distinguishing features of conditions presenting as a red eye are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef77807 \" href=\"UTD.htm?8/8/8334\">",
"     table 3",
"    </a>",
"    ). The specific diagnosis and treatment of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4088?source=see_link\">",
"     \"Eyelid lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link\">",
"     \"Conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=see_link\">",
"     \"Corneal abrasions and corneal foreign bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=see_link\">",
"     \"Angle-closure glaucoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15396?source=see_link\">",
"     \"Photokeratitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link\">",
"     \"Blepharitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of visual acuity and findings on penlight examination are central features in determining management of the red eye. The history and overall patient assessment are useful and confirmatory in the decision to manage or refer. Performance of the slit lamp examination is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44486?source=see_link\">",
"     \"Slit lamp examination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with a red eye call to inquire whether they need to be seen by a clinician. Certain historical features or presenting complaints signal the need for clinician examination and possibly patient referral. The following questions should be asked in all patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is vision affected? &mdash; Can you still read ordinary print with the affected eye? Patients with impaired vision cannot be managed over the phone; they require a clinician examination and may, depending upon the findings, require ophthalmic referral.",
"     </li>",
"     <li>",
"      Is there foreign body sensation? &mdash; Does it feel as though there is something in your eye, interfering with your ability to keep your eye open? A foreign body sensation is the cardinal symptom of an active corneal process.",
"      <strong>",
"       Objective",
"      </strong>",
"      evidence of foreign body sensation, in which the patient is unable to spontaneously open the eye or keep it open, suggests corneal involvement; with the exception of the initial presentation for corneal abrasion or foreign body, such patients warrant emergent or urgent referral to an ophthalmologist. In comparison, many patients report a \"scratchy feeling,\" \"grittiness,\" or a sensation \"like sand in my eyes\" with allergy, viral conjunctivitis, or dry eyes. This is",
"      <strong>",
"       subjective",
"      </strong>",
"      foreign body sensation and does not necessarily suggest a corneal problem that requires referral.",
"     </li>",
"     <li>",
"      Is there photophobia? &mdash; Are you sensitive to bright light? Patients with photophobia should always be examined by a clinician.",
"      <br/>",
"      <br/>",
"      Patients with an active corneal process have objective signs of photophobia as well as objective signs of foreign body sensation. They may present wearing a hat",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sunglasses, are likely to cover the affected eye with the hand to block out light, or keep the head down and turned away from light fixtures or windows. They may request that the examination room lights be left off while waiting for the provider. Patients with iritis have objective signs of photophobia, but no objective foreign body sensation.",
"     </li>",
"     <li>",
"      Was there trauma? &mdash; Have you suffered an injury due to a finger poke, a tool, utensil, or other object? Was there blunt trauma such as a fist or tennis ball?",
"     </li>",
"     <li>",
"      Are you a contact lens wearer? &mdash; A history of contact lens wear in the setting of discharge and a red eye should increase the suspicion of keratitis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17607/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29128?source=see_link&amp;anchor=H13#H13\">",
"       \"Complications of contact lenses\", section on 'Contact lens&ndash;related infectious keratitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Is there discharge, other than tears, that continues throughout the day? &mdash; Morning crusting followed by a watery discharge for the remainder of the day is characteristic of many self-limited processes such as allergy, stye or hordeolum, viral conjunctivitis, allergic conjunctivitis, and dry eyes. Patients typically interpret morning crusting as \"pus.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bacterial conjunctivitis and bacterial keratitis cause opaque discharge that persists throughout the day and requires specific therapy. Bacterial conjunctivitis, which is typically",
"    <strong>",
"     not",
"    </strong>",
"    associated with a reduction in visual acuity, foreign body sensation, or photophobia, may be treated by the primary care clinician. Bacterial keratitis, on the other hand, which may or may not affect vision but typically causes objective foreign body sensation and photophobia, requires emergent referral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;General observation of the patient can provide guidance as to whether the problem is likely to be benign and treatable initially by the primary care clinician or if it requires referral. The subjective report of symptoms and threshold to report symptoms varies among individuals.",
"   </p>",
"   <p>",
"    Lid and conjunctival entities do not cause objective foreign body sensation or photophobia. The patient will be sitting in the examination room with both eyes open, unaffected by the ambient lighting. The patient with viral or allergic conjunctivitis may have signs of or complain of rhinorrhea, lymphadenopathy, or other upper respiratory tract symptoms.",
"   </p>",
"   <p>",
"    In comparison, the patient suffering from infectious keratitis, iritis, or angle-closure glaucoma is likely to have objective signs indicating the more serious nature of the problem. These entities all require ophthalmologic consultation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ophthalmologic examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Measurement of visual acuity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vision should be documented for every patient who is seen for an eye complaint. (An inquiry should be made about a change in vision on every telephone triage). Each eye should be tested separately. Snellen acuity is the standard; however, this test requires using a Snellen chart at 20 feet with best correction or pinhole and is often difficult to perform.",
"   </p>",
"   <p>",
"    An alternative in a triage setting is measurement of near vision. Allow the patient to use his or her usual reading correction if possible and hold a near card or ordinary book, newspaper, or magazine at a comfortable distance. It is not important to determine exactly whether the vision is",
"    <span class=\"nowrap\">",
"     20/30",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    at 12 or 14 inches, but rather to document visual acuity in crude categories: reading vision (small print versus large print); form vision only (hand motions or count fingers); or light perception. This measurement should be made",
"    <strong>",
"     before",
"    </strong>",
"    lights are shined in the eye or drops of any sort are applied.",
"   </p>",
"   <p>",
"    In cases in which a lid disorder, conjunctival process, corneal abrasion, or foreign body is suspected, the presence of normal acuity can be a source of reassurance to the primary care clinician that it is reasonable for them to initiate therapy. On the other hand, if acuity is reduced in the presence of a red eye beyond that which the patient reports is typical, the clinician should suspect one of the more worrisome diagnoses: infectious keratitis, iritis, or angle-closure glaucoma. These patients should be referred for initial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Penlight examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The penlight should be used to examine the pupils and anterior segment. A slit lamp is not required to distinguish those entities that can be treated by the primary care clinician from those entities that must be referred. It is useful to consider the following questions during the penlight examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Does the pupil react to light? &mdash; The pupil is fixed in mid-dilation in cases of angle-closure glaucoma. It does not react to light and is typically 4 to 5 mm in diameter.",
"     </li>",
"     <li>",
"      Is the pupil very small (1 to 2 mm) in size? &mdash; The pupil is pinpoint in cases of corneal abrasion, infectious keratitis, or iritis. Abrasion is distinguished from iritis by the presence of a staining defect on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      examination and an objective foreign body sensation, neither of which is present with iritis. Abrasions are usually caused by focal trauma to the surface of the eye. Traumatic iritis may occur after blunt trauma, a softball, or a fist, but there are no corneal findings.",
"     </li>",
"     <li>",
"      Is there purulent discharge? &mdash; Purulent discharge suggests bacterial conjunctivitis or bacterial keratitis. In conjunctivitis, there are no opacities by penlight or staining defects with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      What is the pattern of redness? &mdash; Diffuse injection involving both the conjunctiva inside the lid (the palpebral conjunctiva) and the conjunctiva on the globe (the bulbar conjunctiva) suggests a primary conjunctival problem such as conjunctivitis. Conjunctivitis may be bacterial, viral, allergic, toxic, or nonspecific (eg, dry eye syndrome). In these entities the entire mucus membrane is equally involved. In comparison, ciliary flush is characteristic of the more serious entities including infectious keratitis, iritis, or angle closure. With ciliary flush, injection is most marked at the limbus (where the cornea undergoes transition to the sclera) and then diminishes toward the equator.",
"      <br/>",
"      <br/>",
"      When the redness appears hemorrhagic rather than in a pattern of injection (dilated blood vessels), the diagnosis of subconjunctival hemorrhage should be considered.",
"     </li>",
"     <li>",
"      Is there a white spot, opacity or foreign body on the cornea? &mdash; A white spot or opacity on the cornea suggests infectious keratitis. This can usually be seen without the aid of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      . Fluorescein is used at the end of the examination to confirm the absence or presence of a corneal process. The white spot of a bacterial keratitis and the raised, grayish branching opacity of herpes simplex keratitis will pick up stain (",
"      <a class=\"graphic graphic_picture graphicRef54460 \" href=\"UTD.htm?16/22/16736\">",
"       picture 1",
"      </a>",
"      ). Abrasions will also pick up stain; however, these are not characterized by the presence of corneal opacity. A corneal foreign body will not pick up stain.",
"     </li>",
"     <li>",
"      Is there hypopyon or hyphema? &mdash; Hypopyon, a layer of white cells in the anterior chamber, or hyphema, a layer of red cells, each require urgent referral to an ophthalmologist (",
"      <a class=\"graphic graphic_picture graphicRef51972 \" href=\"UTD.htm?37/28/38351\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef62031 \" href=\"UTD.htm?3/24/3458\">",
"       picture 3",
"      </a>",
"      ). Hypopyon is associated with sight-threatening infectious keratitis or endophthalmitis until proven otherwise; these patients must be seen by an ophthalmologist within hours. Hyphema is a sign of significant blunt or penetrating trauma to the globe and must also be seen by an ophthalmologist within hours to evaluate for penetrating eye injury, retinal detachment, and acute glaucoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link\">",
"       \"Traumatic hyphema: Clinical features and management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fundus examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fundus examination is typically not helpful in the differential diagnosis of the red eye. In the benign entities such as lid and conjunctival processes, the fundus examination is easily performed and has no associated pathologic features. In iritis and keratitis, the pupil will be very small and the patient photophobic, making the examination difficult to perform. Although the pupil is midsize in angle-closure glaucoma, the fundus examination becomes increasingly difficult to perform as the attack persists because of increasing corneal edema from high intraocular pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SPECIFIC ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of the red eye includes serious conditions that require ophthalmologic evaluation (",
"    <a class=\"graphic graphic_table graphicRef75654 \" href=\"UTD.htm?2/48/2827\">",
"     table 1",
"    </a>",
"    ) and more benign conditions (",
"    <a class=\"graphic graphic_table graphicRef56779 \" href=\"UTD.htm?9/26/9643\">",
"     table 2",
"    </a>",
"    ). Features that can help distinguish these include history, visual acuity, sensation of a foreign body, photophobia, discharge, pupil size and reactivity, pruritus or pain, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    staining (",
"    <a class=\"graphic graphic_table graphicRef77807 \" href=\"UTD.htm?8/8/8334\">",
"     table 3",
"    </a>",
"    ). Photographs of specific conditions show typical features of blepharitis (",
"    <a class=\"graphic graphic_picture graphicRef85896 \" href=\"UTD.htm?7/18/7464\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef85900 \" href=\"UTD.htm?39/17/40212\">",
"     picture 5",
"    </a>",
"    ), episcleritis (",
"    <a class=\"graphic graphic_picture graphicRef85898 \" href=\"UTD.htm?16/4/16454\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef87224 \" href=\"UTD.htm?15/57/16276\">",
"     picture 7",
"    </a>",
"    ), bacterial conjunctivitis (",
"    <a class=\"graphic graphic_picture graphicRef55606 \" href=\"UTD.htm?10/0/10241\">",
"     picture 8",
"    </a>",
"    ), allergic conjunctivitis (",
"    <a class=\"graphic graphic_picture graphicRef57240 \" href=\"UTD.htm?14/20/14670\">",
"     picture 9",
"    </a>",
"    ), corneal abrasion (",
"    <a class=\"graphic graphic_picture graphicRef87225 \" href=\"UTD.htm?23/8/23681\">",
"     picture 10",
"    </a>",
"    ), corneal foreign body (",
"    <a class=\"graphic graphic_picture graphicRef87226 \" href=\"UTD.htm?22/25/22928\">",
"     picture 11",
"    </a>",
"    ), anterior uveitis (",
"    <a class=\"graphic graphic_picture graphicRef85904 \" href=\"UTD.htm?6/4/6214\">",
"     picture 12",
"    </a>",
"    ), hyphema (",
"    <a class=\"graphic graphic_picture graphicRef51972 \" href=\"UTD.htm?37/28/38351\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62031 \" href=\"UTD.htm?3/24/3458\">",
"     picture 3",
"    </a>",
"    ), hypopyon (",
"    <a class=\"graphic graphic_picture graphicRef59911 \" href=\"UTD.htm?1/45/1745\">",
"     picture 13",
"    </a>",
"    ), bacterial keratitis endophthalmitis (",
"    <a class=\"graphic graphic_picture graphicRef85905 \" href=\"UTD.htm?32/3/32821\">",
"     picture 14",
"    </a>",
"    ), angle-closure glaucoma (",
"    <a class=\"graphic graphic_picture graphicRef80395 \" href=\"UTD.htm?22/50/23328\">",
"     picture 15",
"    </a>",
"    ), and subconjunctival hemorrhage (",
"    <a class=\"graphic graphic_picture graphicRef51578 \" href=\"UTD.htm?4/24/4495\">",
"     picture 16",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the section to follow the entities, listed in a table, that require ophthalmic evaluation are summarized (",
"    <a class=\"graphic graphic_table graphicRef75654 \" href=\"UTD.htm?2/48/2827\">",
"     table 1",
"    </a>",
"    ). The most common entities among the benign conditions covered in another table (",
"    <a class=\"graphic graphic_table graphicRef56779 \" href=\"UTD.htm?9/26/9643\">",
"     table 2",
"    </a>",
"    ), conjunctivitis and corneal abrasion, are covered elsewhere. Subconjunctival hemorrhage is common, and is alarming to patients, and is covered here as it does not fall into the other categories. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link\">",
"     \"Conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=see_link\">",
"     \"Corneal abrasions and corneal foreign bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29128?source=see_link\">",
"     \"Complications of contact lenses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84691081\">",
"    <span class=\"h2\">",
"     Angle-closure glaucoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute angle-closure glaucoma is relatively uncommon, but the incidence increases dramatically with age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17607/abstract/4\">",
"     4",
"    </a>",
"    ]. Angle closure leads to increased intraocular pressure (",
"    <a class=\"graphic graphic_figure graphicRef71234 graphicRef59454 \" href=\"UTD.htm?16/22/16743\">",
"     figure 1A-B",
"    </a>",
"    ). The patient with angle-closure glaucoma typically appears to be in general distress. He or she is likely to be slumped over covering the eye or clutching the frontal or temporal region of the head with one hand, complaining of headache and malaise. As angle closure progresses and the intraocular pressure rises, patients develop nausea and in some cases vomiting. The pain of angle closure is a dull ache that is more likely reported as unilateral headache rather than eye pain. Some patients complain of \"the worst headache in my life\" and do not attribute their symptoms to the eye. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=see_link\">",
"     \"Angle-closure glaucoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unnecessary neurologic workup and imaging that may critically delay treatment can be avoided if the red eye is noted and assessed. Acuity becomes increasingly reduced as the duration of the attack increases. These patients may be photophobic. They do not typically complain of a foreign body sensation.",
"   </p>",
"   <p>",
"    Penlight examination reveals a red eye with ciliary flush and no discharge. The pupil is fixed in mid-dilation and the anterior chamber is shallow. Within hours of symptom onset the cornea becomes hazy (",
"    <a class=\"graphic graphic_picture graphicRef80395 \" href=\"UTD.htm?22/50/23328\">",
"     picture 15",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Diagnosis is confirmed with measurement of intraocular pressure. Normal intraocular pressure is 8 to 22 mm Hg; pressures in acute angle closure are often greater than 45 mm Hg.",
"   </p>",
"   <p>",
"    Angle-closure glaucoma is a sight-threatening emergency that must be treated within hours to avoid irreversible damage to the optic nerve. Typically, pressure-lowering topical and systemic agents are administered, and definitive treatment in the form of laser iridotomy is performed that same day by the ophthalmologist. The fellow eye is then treated prophylactically within days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84691166\">",
"    <span class=\"h2\">",
"     Hyphema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyphema refers to the finding of red blood cells layered out in the anterior chamber. This finding warrants same-day evaluation by an ophthalmologist as it can be associated with significant trauma, inflammation, or pathologic neovascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link\">",
"     \"Traumatic hyphema: Clinical features and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84691179\">",
"    <span class=\"h2\">",
"     Hypopyon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypopyon refers to the finding of white blood cells layered out in the anterior chamber. This finding warrants same-day evaluation by an ophthalmologist as it can be associated with infectious keratitis or endophthalmitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=see_link\">",
"     \"Bacterial endophthalmitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84691192\">",
"    <span class=\"h2\">",
"     Iritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation of the anterior uveal tract is called iritis or anterior uveitis; when the adjacent ciliary body is also inflamed the process is called iridocyclitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with iritis may present in a similar fashion to those with an active corneal process but there is no foreign body sensation per se. The patient may choose to keep the eyes closed to block out light but, in a dimly lit environment, the patient is able to keep the affected eye open spontaneously. Patients with an active corneal process and iritis will display an aversive response when the penlight is shined in the affected",
"    <strong>",
"     and",
"    </strong>",
"    in the uninvolved eye.",
"   </p>",
"   <p>",
"    The cardinal sign of iritis is ciliary flush: injection that gives the appearance of a red ring around the iris. Typically, there is no discharge and only minimal tearing.",
"   </p>",
"   <p>",
"    Iritis can be caused by any one of many infections, inflammatory, and infiltrative processes. These include tuberculosis, sarcoidosis, syphilis, toxoplasma, toxocara, and reactive arthritis (formerly called Reiter syndrome). Many cases are idiopathic.",
"   </p>",
"   <p>",
"    Patients with iritis should be seen by an ophthalmologist within a matter of days. The ophthalmologist will initiate treatment, typically with topical steroids, and monitor for side effects and response to therapy. Cases that are bilateral, recurrent, sight-threatening, or non-responsive to therapy will require extensive evaluation for etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Infectious keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious keratitis can be caused by bacteria, viruses, fungi, or parasites [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17607/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bacterial keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial infectious keratitis warrants evaluation by an ophthalmologist on the same day. The patient will complain of foreign body sensation and have trouble keeping the involved eye open, a sign of an active corneal process. Bacterial pathogens include Staphylococcus aureus, Pseudomonas aeruginosa, coagulase-negative Staphylococcus, diphtheroids, Streptococcus pneumoniae, and polymicrobial isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17607/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overnight wear of contact lenses is associated with a higher incidence of bacterial keratitis, but the entity can occur in patients who do not wear contact lenses or who wear them on a daytime only basis. Breakdown in local or systemic host defense mechanisms, including dry ocular surfaces, topical corticosteroid use, and immunosuppression, can predispose to bacterial keratitis.",
"   </p>",
"   <p>",
"    The diagnostic finding in bacterial keratitis is a corneal opacity or infiltrate (typically a round white spot) in association with red eye, photophobia, and foreign body sensation. This infiltrate or ulcer (&gt;0.5 mm in size) can be seen with a penlight, and does not require a slit lamp for identification. It will stain with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    . Mucopurulent discharge is typically present. Fulminant cases may present with an associated hypopyon (layer of white cells in the anterior chamber) (",
"    <a class=\"graphic graphic_picture graphicRef51972 \" href=\"UTD.htm?37/28/38351\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Treatment requires urgent ophthalmological referral and prompt initiation of topical bactericidal antibiotics (ideally after obtaining cultures). These antibiotics are sometimes compounded in fortified concentrations, not commercially available. Topical glucocorticoids and topical drug combinations containing topical steroids should not be used in the initial treatment of suspected bacterial keratitis; their role is controversial and best left to the discretion of the consulting ophthalmologist [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17607/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Viral keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex causes infectious keratitis, characterized by red eye, photophobia, foreign body sensation, and watery discharge. There may be a faint branching grey opacity on penlight exam. This branching opacity is best visualized with application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    . Although typically a self-limited process, duration of symptoms is reduced with treatment with topical or oral antiviral agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33992?source=see_link\">",
"     \"Herpes simplex keratitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be referred to an ophthalmologist within a few days for confirmation of diagnosis, initiation of therapy, and monitoring for response, sequelae, or recurrence. Immunocompromised patients may require topical and systemic treatment, and longer duration of therapy. A small percentage of patients develop chronic or recurrent inflammation, or recurrent viral keratitis, both of which are treated with prophylactic oral antiviral agents. Some patients also benefit from treatment with topical corticosteroid agents, used in conjunction with antiviral prophylaxis, under the care of an ophthalmologist.",
"   </p>",
"   <p>",
"    Adenovirus typically causes conjunctivitis, but some strains in some individuals can cause an associated keratitis (epidemic keratoconjunctivitis or EKC). These patients have classic manifestations of viral conjunctivitis, but within a few days develop symptoms of an active corneal process (photophobia and objective foreign body sensation). Penlight exam of cornea is unremarkable, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    staining reveals multiple punctate staining lesions. Preauricular lymphadenopathy is often present.",
"   </p>",
"   <p>",
"    EKC or adenoviral keratitis is typically a self-limited process without sequelae, although patients are quite miserable during active disease because of photophobia and foreign body sensation. Referral to an ophthalmologist within days is warranted for confirmation of the diagnosis, for monitoring for resolution, and for treatment if there is decline in vision from centrally located viral lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=see_link\">",
"     \"Diagnosis and treatment of adenovirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Subconjunctival hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with subconjunctival hemorrhage are generally asymptomatic. Typically the patient is unaware of a problem until he or she looks in the mirror or is informed of it by someone else. The clinical appearance of subconjunctival hemorrhage, with demarcated areas of extravasated blood just beneath the surface of the eye, is generally both obvious and diagnostic (",
"    <a class=\"graphic graphic_picture graphicRef51578 \" href=\"UTD.htm?4/24/4495\">",
"     picture 16",
"    </a>",
"    ). However, the appearance can be quite alarming to patients and their contacts.",
"   </p>",
"   <p>",
"    Subconjunctival hemorrhage may occur spontaneously or with Valsalva associated with coughing, sneezing, straining, or vomiting. The diagnosis is confirmed by normal acuity and the absence of discharge, photophobia, or foreign body sensation. The blood pressure should be checked to exclude hypertension; however, there is only poor evidence for such an association.",
"   </p>",
"   <p>",
"    The blood is typically resorbed over 1 to 2 weeks, depending on the amount of extravasated blood. Because the subconjunctival space is loculated, the amount of blood may seem to increase on the second day, but this typically represents redistribution. No specific therapy is indicated.",
"   </p>",
"   <p>",
"    If subconjunctival hemorrhage is recurrent or if the patient has a history of bleeding disorder, blood dyscrasia, or is on anticoagulant therapy, then an underlying hematologic or coagulation abnormality must be considered. Eyes with subconjunctival hemorrhage in the setting of blunt trauma must be evaluated for the possibility of ruptured globe or retrobulbar hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=see_link\">",
"       \"Patient information: Conjunctivitis (pinkeye) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/61/29649?source=see_link\">",
"       \"Patient information: Photokeratitis (Arc eye) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=see_link\">",
"       \"Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;If vision is unaffected; the pupil reacts; there is no objective foreign body sensation or photophobia; and there is no corneal opacity, hypopyon, or hyphema, it is reasonable for the primary care clinician to make an initial diagnosis and initiate therapy. The following are indications for emergent (immediate) ophthalmology referral [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17607/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unilateral red eye in a generally uncomfortable patient with nausea and vomiting (suggestive of acute angle-closure glaucoma)",
"     </li>",
"     <li>",
"      Severe ocular pain or a visual deficit in association with a red eye",
"     </li>",
"     <li>",
"      Corneal infiltrate or opacity that stains with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      (sometimes called an \"ulcer\")",
"     </li>",
"     <li>",
"      Hypopyon",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For those entities that require emergent or urgent ophthalmic referral, there is no need for the primary care clinician to initiate therapy unless directed to do so by the consulting ophthalmologist.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17607/abstract/1\">",
"      Dart JK. Eye disease at a community health centre. Br Med J (Clin Res Ed) 1986; 293:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17607/abstract/2\">",
"      Leibowitz HM. The red eye. N Engl J Med 2000; 343:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17607/abstract/3\">",
"      Liesegang TJ. Contact lens-related microbial keratitis: Part I: Epidemiology. Cornea 1997; 16:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17607/abstract/4\">",
"      Teikari J, Raivio I, Nurminen M. Incidence of acute glaucoma in Finland from 1973 to 1982. Graefes Arch Clin Exp Ophthalmol 1987; 225:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17607/abstract/5\">",
"      Forster RK. Conrad Berens Lecture. The management of infectious keratitis as we approach the 21st century. CLAO J 1998; 24:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17607/abstract/6\">",
"      Hindman HB, Patel SB, Jun AS. Rationale for adjunctive topical corticosteroids in bacterial keratitis. Arch Ophthalmol 2009; 127:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17607/abstract/7\">",
"      Cohen EJ. The case against the use of steroids in the treatment of bacterial keratitis. Arch Ophthalmol 2009; 127:103.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6900 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17607=[""].join("\n");
var outline_f17_12_17607=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ophthalmologic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Measurement of visual acuity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Penlight examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fundus examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SPECIFIC ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84691081\">",
"      Angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84691166\">",
"      Hyphema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84691179\">",
"      Hypopyon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84691192\">",
"      Iritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Infectious keratitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bacterial keratitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Viral keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Subconjunctival hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6900\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6900|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/60/11201\" title=\"figure 1A\">",
"      Angle anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/50/40738\" title=\"figure 1B\">",
"      Angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6900|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/22/16736\" title=\"picture 1\">",
"      Eye manifestations HSV 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/28/38351\" title=\"picture 2\">",
"      Hyphema associated with endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/24/3458\" title=\"picture 3\">",
"      Traumatic hyphema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/18/7464\" title=\"picture 4\">",
"      Blepharitis eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/17/40212\" title=\"picture 5\">",
"      Blepharitis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/4/16454\" title=\"picture 6\">",
"      Episcleritis nodular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/57/16276\" title=\"picture 7\">",
"      Typical form episcleritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/0/10241\" title=\"picture 8\">",
"      Bacterial conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/20/14670\" title=\"picture 9\">",
"      Acute seasonal conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/8/23681\" title=\"picture 10\">",
"      Corneal abrasion II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/25/22928\" title=\"picture 11\">",
"      Corneal foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/4/6214\" title=\"picture 12\">",
"      Anterior uveitis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/45/1745\" title=\"picture 13\">",
"      Hypopyon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/3/32821\" title=\"picture 14\">",
"      Bacterial keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/50/23328\" title=\"picture 15\">",
"      Angle closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/24/4495\" title=\"picture 16\">",
"      Subconjunctival hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6900|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2827\" title=\"table 1\">",
"      Red eye that needs referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/26/9643\" title=\"table 2\">",
"      Red eye treated by primary care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/8/8334\" title=\"table 3\">",
"      Assessment of the red eye",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=related_link\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=related_link\">",
"      Angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=related_link\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29128?source=related_link\">",
"      Complications of contact lenses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=related_link\">",
"      Corneal abrasions and corneal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=related_link\">",
"      Diagnosis and treatment of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4088?source=related_link\">",
"      Eyelid lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33992?source=related_link\">",
"      Herpes simplex keratitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/61/29649?source=related_link\">",
"      Patient information: Photokeratitis (Arc eye) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15396?source=related_link\">",
"      Photokeratitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44486?source=related_link\">",
"      Slit lamp examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_12_17608="Hyponatremia in patients with cirrhosis";
var content_f17_12_17608=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyponatremia in patients with cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/12/17608/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17608/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17608/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/12/17608/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17608/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/12/17608/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17608/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/12/17608/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia is a common problem in patients with advanced cirrhosis. The pathogenesis of hyponatremia in these patients is directly related to the hemodynamic changes and secondary neurohumoral adaptations that occur, resulting in an impaired ability to excrete ingested water. The severity of the hyponatremia is related to the severity of the cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\", section on 'Water retention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of factors can contribute to the development of hyponatremia in patients with cirrhosis. The most important factor is systemic vasodilation, which leads to activation of endogenous vasoconstrictors including antidiuretic hormone (ADH); ADH promotes the water retention that is responsible for the fall in serum sodium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Systemic vasodilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic vasodilation plays a central role in the pathogenesis of hyponatremia in patients with cirrhosis and ascites. These patients usually have a marked reduction in systemic vascular resistance (SVR) and in mean arterial pressure and an increase in cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The vascular territory in which the reduced SVR is most obvious is the splanchnic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of vasodilation in other vascular territories is less obvious and the subject of controversy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. As an example, the factors that cause splanchnic vasodilatation may have a biphasic effect on the renal circulation. Early in the course of the disease &mdash; stable cirrhosis without ascites &mdash; the dilating substances also may influence the renal vasculature and the glomerular filtration rate may be greater than normal (150 versus 105",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in one study) at this stage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/8\">",
"     8",
"    </a>",
"    ]. With more severe disease, the splanchnic vasodilatation becomes more marked, resulting in a fall in mean arterial pressure and decreased renal perfusion, leading in some patients to the hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise mechanisms of vasodilation in cirrhosis have become better understood, with increased generation of nitric oxide and prostaglandins appearing to play an important role (",
"    <a class=\"graphic graphic_algorithm graphicRef81659 \" href=\"UTD.htm?4/63/5104\">",
"     algorithm 1",
"    </a>",
"    ). Nitric oxide production may be stimulated by absorbed endotoxin from the gastrointestinal tract, which is less efficiently cleared due to portal-systemic shunting and decreased reticuloendothelial cell function in cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=see_link\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Activation of endogenous vasoconstrictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reduction in pressure (or stretch) at the carotid and renal baroreceptors induced by cirrhotic vasodilation leads to activation of the sodium- and water-retaining neurohumoral mechanisms in an attempt to restore perfusion pressure to normal (",
"    <a class=\"graphic graphic_algorithm graphicRef81659 \" href=\"UTD.htm?4/63/5104\">",
"     algorithm 1",
"    </a>",
"    ). These include the renin-angiotensin system, the sympathetic nervous system, and antidiuretic hormone (vasopressin). The secretion of these three \"hypovolemic\" hormones is proportional to the severity of the hemodynamic insufficiency (",
"    <a class=\"graphic graphic_figure graphicRef74244 \" href=\"UTD.htm?36/51/37693\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is avid renal sodium and water retention because the patient is effectively volume depleted even though extracellular sodium stores, the plasma volume, and the cardiac output are increased. Sodium retention leads to the development of ascites unless the patient is adequately treated with dietary sodium restriction and diuretics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"     \"Initial therapy of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Water retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water excretion is usually normal in patients with cirrhosis before the development of ascites and then becomes increasingly impaired as the liver disease progresses. This abnormality is largely related to the increased release of antidiuretic hormone (ADH) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], since suppression of ADH release is required to excrete a water load. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenetic importance of ADH in water retention has been demonstrated in rats with cirrhosis in which the administration of a vasopressin (ADH) receptor antagonist restores near normal water excretory ability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/14\">",
"     14",
"    </a>",
"    ]. Although of lesser importance, the renal vasoconstriction and reduction in renal blood flow induced by neurohumoral activation also may contribute to diminished water excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inability to excrete water normally leads to the development of hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, patients who have cirrhosis with ascites typically demonstrate urinary sodium retention, increased total body sodium, increased total body water, and hypotonic hyponatremia.",
"   </p>",
"   <p>",
"    Because the increase in ADH secretion (and therefore the degree of water retention) is roughly proportional to the severity of the cirrhosis (",
"    <a class=\"graphic graphic_figure graphicRef74244 \" href=\"UTD.htm?36/51/37693\">",
"     figure 1",
"    </a>",
"    ), the degree of hyponatremia parallels the severity of the hepatic disease and is, along with the degree of sodium retention, of prognostic value. A serum sodium concentration below 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    carries a relatively poor prognosis, whereas values below 125",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    often indicate impending hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two factors other than high ADH levels may contribute to the tendency toward hyponatremia in selected patients with cirrhosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diuretic therapy can exacerbate the reduction in tissue perfusion, further impairing the ability to excrete free water [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/18\">",
"       18",
"      </a>",
"      ]. This is most likely to occur with rapid fluid removal in patients with ascites but no peripheral edema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"       \"Initial therapy of ascites in patients with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Large volume beer drinkers ingest a large volume of fluid, thereby increasing the tendency to hyponatremia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia is common in patients with cirrhosis. In an international prospective study involving 997 patients in 28 Liver Units, the prevalence of a serum sodium concentration less than 135, 130, 125, and 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in patients with cirrhosis and ascites was 50, 22, 6, and 1 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/20\">",
"     20",
"    </a>",
"    ]. The prevalence was high in both inpatients and outpatients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREDICTOR OF ADVERSE PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In keeping with the correlation between hyponatremia and systemic hemodynamics in cirrhosis, the presence of hyponatremia is associated in a graded fashion with severe ascites (high prevalence of refractory ascites, large fluid accumulation rate, frequent use of large-volume paracentesis), impaired renal function, and higher rates of hepatic encephalopathy, spontaneous bacterial peritonitis, and hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyponatremia is also a powerful predictor of death in patients with cirrhosis and ascites who are on the wait list for a liver transplant. In three studies, for example, serum sodium concentrations of less than 135, 126, or 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    were independent risk factors for death in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The current system for prioritizing patients for liver transplantation uses the serum bilirubin, serum creatinine, and international normalized ratio (INR) for the prothrombin time to calculate the Model for End-stage Liver Disease (MELD) score. Adding hyponatremia to the MELD score is a better predictor of death than the MELD score alone, particularly in patients with low MELD scores [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link&amp;anchor=H72087828#H72087828\">",
"     \"Model for End-stage Liver Disease (MELD)\", section on 'Serum sodium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of the effect of serum sodium on prognosis in patients with end-stage liver disease was evaluated in a report of the 6769 candidates for primary liver transplantation who were registered in the Organ Procurement and Transplantation Network in the United States in 2005 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/25\">",
"     25",
"    </a>",
"    ]. The hazard rate for death was 1.05 per 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    decrease in serum sodium at values between 140 and 125",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    In addition to being a risk factor for death, low serum sodium concentrations (particularly below 130",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    are associated with an increased risk of the osmotic demyelination syndrome with severe neurologic dysfunction shortly after liver transplantation. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Hypertonic saline, osmotic demyelination, and liver transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia in patients with cirrhosis typically develops slowly (paralleling the rate of progression of the liver disease) and usually produces no obvious clinical manifestations until the serum sodium concentration falls below 120",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    which occurred in only 1 percent of patients with cirrhosis in a multicenter series of 997 consecutive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum sodium concentrations do not usually fall spontaneously below 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in patients with cirrhosis until they are close to death or there has been an overly aggressive diuresis, as with the addition of a thiazide diuretic to maximum doses of a loop diuretic (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    . Referral for liver transplantation should be considered in patients who develop this advanced degree of cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1352239\">",
"    <span class=\"h2\">",
"     Decision to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of the hyponatremia has no effect on the hemodynamic abnormalities associated with the severe underlying liver disease, and there are no data that increasing the serum sodium concentration in patients with cirrhosis improves morbidity or mortality. Because of the lack of clear benefit to the patient, the potential side effects and costs of therapy, and the dismal prognosis of patients with cirrhosis who have severe hyponatremia and are not candidates for a liver transplant, some experts do",
"    <strong>",
"     not",
"    </strong>",
"    recommend efforts to raise the serum sodium in this setting.",
"   </p>",
"   <p>",
"    If treatment of the hyponatremia is desired in patients who are not candidates for liver transplantation or for whom liver transplantation is not imminent, the main indications are neurologic symptoms that might be due to hyponatremia or a serum sodium less than 120",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    which occurs in about 1 percent of patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/20\">",
"     20",
"    </a>",
"    ]. For patients in whom liver transplantation is imminent, treatment can be initiated when the serum sodium is less than 130",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Hypertonic saline, osmotic demyelination, and liver transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54245858\">",
"    <span class=\"h2\">",
"     Therapeutic modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Raising the serum sodium is often difficult in patients with advanced cirrhosis. Patients with symptoms that may be attributable to hyponatremia are often initially treated with hypertonic saline. The major options to achieve a sustained increase in the serum sodium are fluid restriction and vasopressin receptor antagonists. In addition, if present, hypokalemia should be corrected since this will tend to raise the serum sodium.",
"   </p>",
"   <p>",
"    When patients with advanced cirrhosis and hyponatremia are treated, overly rapid correction of hyponatremia should be avoided because of the possible induction of severe neurologic injury, called the osmotic demyelination syndrome. The rate of correction should be less than 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    during any 24 hour period and less than 18",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    during any 48 hour period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fluid restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although fluid restriction is frequently employed in patients with cirrhosis and ascites because of concerns related to hyponatremia, such an approach is not supported by the available data.",
"   </p>",
"   <p>",
"    Proper patient selection for fluid restriction is important since, in our experience, fluid restriction tends to alienate the patient, family, nurses, and dietitians without proven benefit. One of the important limitations to compliance with fluid restriction is that the systemic vasodilation that stimulates ADH release (",
"    <a class=\"graphic graphic_figure graphicRef74244 \" href=\"UTD.htm?36/51/37693\">",
"     figure 1",
"    </a>",
"    ) also enhances thirst. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Activation of endogenous vasoconstrictors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is much confusion about the degree of fluid restriction. Some physicians order 1000 mL or 1500 mL free water restriction per day. Some nurses and dietitians include all fluids and others include only fluids on the tray. However, for fluid restriction to raise the serum sodium, the total fluid intake should be less than the urine volume, which is usually quite low; as a result, fluid restriction is often difficult to achieve in patients with cirrhosis who have hyponatremia. Sucking on ice chips or lollipops may be helpful in patients with severe thirst.",
"   </p>",
"   <p>",
"    We attempt to limit fluid intake when the serum sodium is less than 120",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    which only occurs in about 1 percent of patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/20\">",
"     20",
"    </a>",
"    ]. Fluid restriction may also be warranted at somewhat higher serum sodium concentrations (120 to 129",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    in patients who have impaired mentation that might be due to hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/26\">",
"     26",
"    </a>",
"    ] or in patients awaiting liver transplantation. If the serum sodium concentration does not increase within the first 48 to 72 hours, the degree of fluid restriction has been insufficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Correction of hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia in patients with cirrhosis can result from increased urinary losses due to diuretic therapy or increased gastrointestinal losses in patients with diarrhea or vomiting. Hypokalemia, which may be accompanied by metabolic alkalosis, can promote the development of hepatic encephalopathy, by at least two mechanisms: hypokalemia increases renal ammonia synthesis, which delivers additional ammonia into the systemic circulation; alkalemia increases the fraction of unionized ammonia in the plasma. Unionized ammonia more readily penetrates cells, including brain cells, which can worsen hepatic encephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=see_link&amp;anchor=H4#H4\">",
"     \"Hepatic encephalopathy in adults: Treatment\", section on 'Correction of hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, since potassium is as osmotically active as sodium, the administration of potassium will also tend to raise the serum sodium concentration. The mechanism by which this occurs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Effect of potassium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Vasopressin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple receptors for vasopressin (ADH): the V1a, V1b, and V2 receptors. The V2 receptors primarily mediate the antidiuretic response, while V1a and V1b receptors principally cause vasoconstriction and mediate adrenocorticotropin release, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vasopressin receptor antagonists produce a selective water diuresis without affecting sodium and potassium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The ensuing loss of free water will tend to correct the hyponatremia in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/26,29,30\">",
"     26,29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Vasopressin receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some oral formulations &mdash;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    , satavaptan, and lixivaptan &mdash; are selective for the V2 receptor, while an intravenous agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"     conivaptan",
"    </a>",
"    , blocks both the V2 and V1a receptors. Only tolvaptan and conivaptan are currently available in the United States.",
"   </p>",
"   <p>",
"    There is concern that V1a receptor blockade with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"     conivaptan",
"    </a>",
"    may result in both a reduction in blood pressure, which is already low in most such patients, and an increase in the risk of variceal bleeding, given the efficacy of vasopressin in the treatment of active variceal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/27\">",
"     27",
"    </a>",
"    ]. A V1a antagonist might also compromise renal function, since treatment with the V1a agonist, terlipressin, improves renal function in patients with cirrhosis and ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/31\">",
"     31",
"    </a>",
"    ]. As a result, conivaptan should be used with",
"    <strong>",
"     caution",
"    </strong>",
"    in patients with cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of active variceal hemorrhage\", section on 'Intravenous vasopressin and its analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ability of selective V2 receptor antagonists to raise the serum sodium in patients with cirrhosis who are hyponatremic has been demonstrated in two randomized trials (SALT-1 and SALT-2); hyponatremic patients with heart failure and the syndrome of inappropriate antidiuretic hormone secretion were also included [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/26,29\">",
"     26,29",
"    </a>",
"    ]. The mean serum sodium at baseline in these trials was 129 and 127",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    raised the serum sodium significantly more than placebo (approximately 7.0 versus 2.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among all patients in these trials (ie, not just those with cirrhosis) who had a serum sodium below 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    was also associated improved mental status scores compared with placebo. However, this difference, although statistically significant, was usually not clinically significant. Furthermore, long-term efficacy is uncertain since the duration of follow-up was only 30 days.",
"   </p>",
"   <p>",
"    In an open-label extension of the SALT trials (called SALTWATER), 111 patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    for a mean follow-up of almost two years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/32\">",
"     32",
"    </a>",
"    ]. The mean serum sodium was maintained at more than 135",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    compared with 131",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline. The serum sodium responses to tolvaptan were more modest in patients with cirrhosis than in SIADH and heart failure. The main adverse effects were abnormally frequent urination, thirst, dry mouth, fatigue, polyuria, and polydipsia. Adverse effects that were possibly or probably related to tolvaptan led to discontinuation of therapy in six patients (5.4 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major potential adverse effects associated with oral V2 receptor antagonists:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased thirst, which may limit the rise in serum sodium [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/26,29\">",
"       26,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overly rapid correction of the hyponatremia, which can lead to irreversible neurologic injury. In the SALT trials, 1.8 percent of patients exceeded the study goal of limiting daily correction to 12",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/26\">",
"       26",
"      </a>",
"      ]. However, more recent recommendations have suggested a maximum rate of correction of hyponatremia of less than 10",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      not &le;12",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Thus, it is almost certain that more than 1.8 percent of treated patients exceeded the currently recommended rate of correction. Because of this risk, hospitalization is",
"      <strong>",
"       mandatory",
"      </strong>",
"      (FDA black box warning) for the initiation or reinitiation of therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of the treatment of hyponatremia\", section on 'Rate of correction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link\">",
"       \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another limiting factor is the",
"    <strong>",
"     cost",
"    </strong>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    , which is as high as $300 per tablet in some areas (approximately $10,000 per month) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    and, where available, other oral selective V2 receptor antagonists may have a role in the management of hyponatremia in patients with cirrhosis in whom there are indications for raising the serum sodium. (See",
"    <a class=\"local\" href=\"#H1352239\">",
"     'Decision to treat'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1352643\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"     Demeclocycline",
"    </a>",
"    , a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    derivative that increases free water excretion by partially antagonizing the action of ADH, has been evaluated for the treatment of hyponatremia in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/34\">",
"     34",
"    </a>",
"    ]. However, demeclocycline should",
"    <strong>",
"     not",
"    </strong>",
"    be used in patients with cirrhosis because of the common development of nephrotoxicity; this problem is due in part to high circulating drug levels that result from diminished hepatic drug metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypertonic saline, osmotic demyelination, and liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertonic saline is generally warranted only in patients with cirrhosis who are profoundly hyponatremic and are within hours of liver transplantation. Partial correction before transplantation is preferable to rapid correction in the operating room. As noted above, in patients who have profound hyponatremia and are not candidates for liver transplantation, treatment to raise the serum sodium may provide limited benefit since these patients are close to death and there are no data that increasing the serum sodium will improve morbidity or mortality. (See",
"    <a class=\"local\" href=\"#H1352239\">",
"     'Decision to treat'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When hypertonic saline is given, overly rapid correction (10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or more at 24 hours and 18",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or more at 48 hours) should be",
"    <strong>",
"     avoided",
"    </strong>",
"    to minimize the risk of central demyelinating lesions with neurologic dysfunction, which is called the osmotic demyelination syndrome (ODS, also called central pontine and extrapontine myelinolysis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link&amp;anchor=H7#H7\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\", section on 'Rapid rate of correction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overly rapid correction of hyponatremia can also occur after liver transplantation. In different studies, the rate of ODS after liver transplantation ranged from 5 to 29 percent in patients with hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. The median time to onset of ODS in reported cases is 5 to 7 days; late development beyond 12 days is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/39\">",
"     39",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 2175 liver transplant recipients, 10 (0.5 percent) developed ODS after transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/36\">",
"       36",
"      </a>",
"      ]. The mean baseline serum sodium concentration was 129",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in the patients who developed ODS, significantly lower than the mean value of 136",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in those who did not. The likelihood of developing ODS increased with lower baseline serum sodium concentrations: 0.1, 0.8, and 4.6 percent at serum sodium concentrations of 135",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or higher, 125 to 134",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      and less than 125",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      respectively. Data were not available on the use of hypertonic saline or on the rate of correction of the serum sodium.",
"     </li>",
"     <li>",
"      Another large retrospective study evaluated 379 liver transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/38\">",
"       38",
"      </a>",
"      ]. Among 12 patients with a serum sodium less than or equal to 127",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      ODS developed in 3 (25 percent). The rise in serum sodium during transplantation in these patients was 21",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      compared to only 7",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in those who did not develop ODS. A third study found a similar rate of ODS following liver transplantation (29 percent [4 of 14 patients]) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/37\">",
"       37",
"      </a>",
"      ]. The serum sodium concentration prior to surgery in these four patients was markedly reduced in two. The perioperative rise in serum sodium was 21 to 32",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      with the maximum increase on the day of surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, ODS after liver transplantation primarily occurs in patients who have a baseline serum sodium concentration below 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and a rapid elevation in the serum sodium in the peritransplant period. In the last study, none of the four patients who developed ODS was treated with hypertonic saline [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/37\">",
"     37",
"    </a>",
"    ]. This observation suggests that restoration of hepatic function alone",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    the large volumes of isotonic fluid administered intraoperatively) is sufficient to induce rapid correction of hyponatremia, and provides support for partial, slow correction of hyponatremia",
"    <strong>",
"     prior",
"    </strong>",
"    to transplantation in patients with serum sodium concentrations of 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less. However, this approach will not protect all patients, since pontine and extrapontine myelinolysis can occur in patients who are not hyponatremic prior to liver transplantation and do not have a rapid elevation in serum sodium after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17608/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/20/9537?source=see_link\">",
"       \"Patient information: Hyponatremia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14371133\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyponatremia is a common problem in patients with advanced cirrhosis; the severity of the hyponatremia is related to the severity of the cirrhosis (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important factor in the development of hyponatremia in patients with cirrhosis is systemic vasodilation, which leads to activation of endogenous vasoconstrictors including antidiuretic hormone (ADH); ADH promotes the water retention that is responsible for the fall in serum sodium. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyponatremia is a powerful predictor of death in patients with cirrhosis and ascites, and adding hyponatremia to the Model for End-stage Liver Disease (MELD) score is a better predictor of death than the MELD score alone. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Predictor of adverse prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the lack of clear benefit to the patient, the potential side effects and costs of therapy, and the overall dismal prognosis of patient with cirrhosis with severe hyponatremia, some experts do",
"      <strong>",
"       not",
"      </strong>",
"      recommend efforts to raise the serum sodium. (See",
"      <a class=\"local\" href=\"#H1352239\">",
"       'Decision to treat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If treatment of the hyponatremia is desired in patients who are not candidates for liver transplantation or for whom liver transplantation is not imminent, the main indications are neurologic symptoms that might be due to hyponatremia or a serum sodium less than 120",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1352239\">",
"       'Decision to treat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Raising the serum sodium is often difficult in patients with advanced cirrhosis. The major options to achieve a sustained increase in the serum sodium are fluid restriction and vasopressin receptor antagonists. (See",
"      <a class=\"local\" href=\"#H54245858\">",
"       'Therapeutic modalities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fluid restriction is difficult to achieve in patients with cirrhosis and hyponatremia for two reasons: these patients often complain of thirst; and, for fluid restriction to raise the serum sodium, the total fluid intake should be less than the urine volume, which is typically quite low. Sucking on ice chips or lollipops may be helpful in patients with severe thirst (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Fluid restriction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vasopressin receptor antagonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      may have a role in the management of hyponatremia in patients with cirrhosis in whom there are indications for raising the serum sodium. Hospitalization is",
"      <strong>",
"       mandatory",
"      </strong>",
"      (FDA black box warning) for initiation or reinitiation of therapy to prevent overly rapid correction of the hyponatremia. The other major potential adverse effect is increased thirst. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Vasopressin receptor antagonists'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with cirrhosis who are treated for hyponatremia, we recommend that the rate of correction should be less than 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at 24 hours and less than 18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at 48 hours. The rationale for this recommendation is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of the treatment of hyponatremia\", section on 'Rate of correction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with a serum sodium concentration less than 130",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in whom liver transplantation is imminent, we recommend administration of hypertonic saline prior to transplantation to partially correct the hyponatremia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Liver transplantation quickly restores hepatic function which, along with large volumes of isotonic fluids given during surgery, may result in rapid correction of hyponatremia in patients with cirrhosis. Low pretransplant serum sodium concentrations (particularly below 130",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      are associated with an increased risk of osmotic demyelination syndrome with severe neurologic dysfunction shortly after transplantation. Preoperative use of hypertonic saline may minimize the risk of overly rapid correction after transplantation and, in a monitored setting, has low potential for harm. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hypertonic saline, osmotic demyelination, and liver transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/1\">",
"      Gin&egrave;s P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008; 48:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/2\">",
"      KOWALSKI HJ, ABELMANN WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/3\">",
"      Abelmann WH. Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology 1994; 20:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/4\">",
"      Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994; 20:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/5\">",
"      Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/6\">",
"      Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/7\">",
"      Maroto A, Gin&egrave;s P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/8\">",
"      Wong F, Massie D, Colman J, Dudley F. Glomerular hyperfiltration in patients with well-compensated alcoholic cirrhosis. Gastroenterology 1993; 104:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/9\">",
"      Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/10\">",
"      Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/11\">",
"      Asbert M, Gin&egrave;s A, Gin&egrave;s P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993; 104:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/12\">",
"      Henriksen JH, Bendtsen F, Gerbes AL, et al. Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/13\">",
"      Arroyo V, Bosch J, Gaya-Beltr&aacute;n J, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/14\">",
"      Tsuboi Y, Ishikawa S, Fujisawa G, et al. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994; 46:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/15\">",
"      Sacerdoti D, Bolognesi M, Merkel C, et al. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 1993; 17:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/16\">",
"      Arroyo V, Cl&agrave;ria J, Sal&oacute; J, Jim&eacute;nez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994; 14:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/17\">",
"      Papadakis MA, Fraser CL, Arieff AI. Hyponatraemia in patients with cirrhosis. Q J Med 1990; 76:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/18\">",
"      Sherlock S, Senewiratne B, Scott A, Walker JG. Complications of diuretic therapy in hepatic cirrhosis. Lancet 1966; 1:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/19\">",
"      Hilden T, Svendsen TL. Electrolyte disturbances in beer drinkers. A specific \"hypo-osmolality syndrome\". Lancet 1975; 2:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/20\">",
"      Angeli P, Wong F, Watson H, et al. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006; 44:1535.",
"     </a>",
"    </li>",
"    <li>",
"     Runyon, BA. Ascites returns to the spotlight. Clinical Care Options for Hepatitis. www.clinicaloptions.com/hep/jopt/articles.asp?a=Heuman-Hepatol-2004-10&amp;page=commentary.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/22\">",
"      Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/23\">",
"      Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/24\">",
"      Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/25\">",
"      Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/26\">",
"      Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/27\">",
"      Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/28\">",
"      Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/29\">",
"      Gerbes AL, G&uuml;lberg V, Gin&egrave;s P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003; 124:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/30\">",
"      Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/31\">",
"      Krag A, M&oslash;ller S, Henriksen JH, et al. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007; 46:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/32\">",
"      Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/33\">",
"      Boyer TD. Tolvaptan and hyponatremia in a patient with cirrhosis. Hepatology 2010; 51:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/34\">",
"      Forrest JN Jr, Cox M, Hong C, et al. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1978; 298:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/35\">",
"      Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 1980; 243:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/36\">",
"      Yun BC, Kim WR, Benson JT, et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology 2009; 49:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/37\">",
"      Wszolek ZK, McComb RD, Pfeiffer RF, et al. Pontine and extrapontine myelinolysis following liver transplantation. Relationship to serum sodium. Transplantation 1989; 48:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/38\">",
"      Abbasoglu O, Goldstein RM, Vodapally MS, et al. Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. Clin Transplant 1998; 12:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17608/abstract/39\">",
"      Bonham CA, Dominguez EA, Fukui MB, et al. Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management. Transplantation 1998; 66:1596.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2326 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17608=[""].join("\n");
var outline_f17_12_17608=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14371133\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Systemic vasodilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Activation of endogenous vasoconstrictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Water retention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREDICTOR OF ADVERSE PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1352239\">",
"      Decision to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54245858\">",
"      Therapeutic modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fluid restriction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Correction of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Vasopressin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1352643\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypertonic saline, osmotic demyelination, and liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14371133\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2326\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2326|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?4/63/5104\" title=\"algorithm 1\">",
"      Hemodynamics in cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2326|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/51/37693\" title=\"figure 1\">",
"      Hormonal response to cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=related_link\">",
"      Hepatic encephalopathy in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/20/9537?source=related_link\">",
"      Patient information: Hyponatremia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=related_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_12_17609="Literacy and patient care";
var content_f17_12_17609=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Literacy and patient care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/12/17609/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17609/contributors\">",
"     Urmimala Sarkar, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17609/contributors\">",
"     Dean Schillinger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/12/17609/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17609/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/12/17609/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17609/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/12/17609/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective healthcare relies on the ability to communicate with patients. Many publications have recognized that limited patient literacy is a barrier to medical diagnosis and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. We rely increasingly upon patient knowledge and skills to manage chronic diseases such as asthma, diabetes, and congestive heart failure. Patients need to understand concepts of risk and probability in order to make informed choices about screening and treatment and thereby act as true partners in the patient-doctor relationship.",
"   </p>",
"   <p>",
"    At the most fundamental level, limited literacy increases the linguistic, social, and cultural gap between clinician and patient, making mutual understanding more difficult. Interventions at the patient-physician level and at the practice level can help improve quality of care for the large population of patients with limited literacy skills.",
"   </p>",
"   <p>",
"    This topic will review the impact of health literacy on patient care, health literacy screening, and ways to improve communication for patients with limited health literacy. Issues related to cross cultural care are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24537?source=see_link\">",
"     \"Cross-cultural care and communication\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low literacy in the United States (US) is surprisingly common; most clinicians encounter patients with low literacy daily. The many challenges that limited literacy poses in obtaining high quality health care have led to the development of the term \"health literacy\". A systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/5\">",
"     5",
"    </a>",
"    ] and a 2004 report from the Institute of Medicine (IOM) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/6\">",
"     6",
"    </a>",
"    ] use the following definition of health literacy: \"The degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.\"",
"   </p>",
"   <p>",
"    Limited health literacy has the most impact and is found most frequently in those with low global literacy, although some individuals with limited health literacy do have adequate literacy skills in other arenas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The average reading level of the US population is estimated at the eighth grade level. The 2003 National Assessment of Adult Literacy (NAAL) assessed the English literacy of a sample of adults in the US and found that over 75 million adults had \"basic\" or \"below basic\" literacy (",
"    <a class=\"graphic graphic_figure graphicRef56350 \" href=\"UTD.htm?11/57/12190\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef80573 \" href=\"UTD.htm?43/21/44382\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/8\">",
"     8",
"    </a>",
"    ]. Definitions of literacy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proficient &mdash; Able to define medical term from complex document, can calculate share of employee&rsquo;s health insurance costs",
"     </li>",
"     <li>",
"      Intermediate &mdash; Able to determine healthy weight from BMI chart, can interpret prescription and over-the-counter drug labels",
"     </li>",
"     <li>",
"      Basic &mdash; Understand simple patient education handout",
"     </li>",
"     <li>",
"      Below Basic &mdash; Circle date on appointment slip, unable to understand simple pamphlet about pre-test instructions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women had slightly higher literacy scores than men. Limited literacy was more common among those aged 65 or older, those receiving Medicare or Medicaid, and those with less than a high school education (",
"    <a class=\"graphic graphic_figure graphicRef55333 \" href=\"UTD.htm?13/53/14160\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68119 \" href=\"UTD.htm?20/37/21086\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Health literacy scores are related to literacy scores [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/9\">",
"     9",
"    </a>",
"    ]. Lower health literacy was found for the following adults [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No high school diploma or GED",
"     </li>",
"     <li>",
"      Activity restrictions related to health issues",
"     </li>",
"     <li>",
"      Members of minority population groups",
"     </li>",
"     <li>",
"      Immigrants",
"     </li>",
"     <li>",
"      Patients with one or more chronic diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study of 3260 new Medicare managed care enrollees found that 40 percent of English speakers and 54 percent of Spanish speakers had inadequate or marginal health literacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/11\">",
"     11",
"    </a>",
"    ]. Importantly, a report from Educational Testing Service predicts that the nation is at great risk of declining health literacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SIGNIFICANCE AND IMPACT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a growing literature about the consequences of poor health literacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/4\">",
"     4",
"    </a>",
"    ]. Health literacy is thought to impact health via three pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Access and utilization of health care",
"     </li>",
"     <li>",
"      Patient-provider relationship",
"     </li>",
"     <li>",
"      Self-care",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low literacy is an independent risk factor for worse outcomes, including increased mortality, lower satisfaction with care, lower quality of care, worse patient safety, and higher health care costs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/1,10,15-19\">",
"     1,10,15-19",
"    </a>",
"    ]. Representative findings include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After adjustment for age, baseline health status, and socioeconomic position, the hazard ratio for all cause mortality was 1.47 (95% CI 1.20-1.79) for participants with low health literacy followed for over five years in the English Longitudinal Study of Ageing [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/20\">",
"       20",
"      </a>",
"      ]. The mortality rate for those with limited literacy was increased twofold compared to adults with adequate literacy in a five-year prospective study of 2500 older adults and remained significantly increased (HR 1.75, 95% CI 1.3-2.4) after adjustment for socioeconomic status, comorbidities, and health-related behaviors [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/21\">",
"       21",
"      </a>",
"      ]. Impaired literacy had a slightly smaller impact on mortality (HR 1.27, 1.03-1.57) when literacy was adjusted for cognitive ability in another study of older adults [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/22\">",
"       22",
"      </a>",
"      ]. Similar mortality results were seen among a cohort of patients from a Medicare managed care setting [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pregnant women with lower health literacy were more likely to exhibit symptoms of depression [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with asthma, whose parents had limited health literacy, had higher rates of hospitalization and rescue medication use [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Kidney transplant patients with lower health literacy had worse kidney function (higher creatinine) after transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Older adults with lower health literacy were found to have poorer overall physical and mental health, more difficulty with activities of daily living, more health care utilization, and higher medical costs [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/17,27,28\">",
"       17,27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inadequate health literacy was associated with worse glycemic control and higher complication rates in patients with type 2 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/16\">",
"       16",
"      </a>",
"      ]. Patients with limited literacy in this study were more likely to report poor physician-patient communication, including difficulties understanding technical terminology and shared decision-making [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Poor health knowledge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low literacy presents numerous ethical challenges, such as impeding the informed consent process [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/30\">",
"     30",
"    </a>",
"    ]. In one study involving patients at two public hospitals, 40 to 74 percent did not adequately comprehend the standard informed consent forms used for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low literacy is associated with poorer patient knowledge of their disease, poorer understanding of medication use, and increased difficulty in navigating the health care system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited literacy was the strongest independent predictor of poor knowledge of the goals of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      treatment and its associated",
"      <span class=\"nowrap\">",
"       risks/benefits",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/32\">",
"       32",
"      </a>",
"      ]. Limited literacy skills was predictive of poor INR control, placing patients at risk for stroke or bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with low health literacy were three times as likely to be unable to name any of their antihypertensive medications than patients with adequate health literacy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with low literacy have difficulty understanding medication instructions. In one study, although 71 percent of patients with low literacy correctly stated the instructions \"Take two tablets by mouth twice daily\", only 35 percent could demonstrate the correct number of pills to be taken daily [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/36\">",
"       36",
"      </a>",
"      ]. The majority of patients with limited health literacy were unable to correctly interpret prescription drug warning labels [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      21 to 31 percent of patients at two public hospitals could not understand a standard appointment slip [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with limited health literacy are less likely to be able to identify a correct portion size [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/38\">",
"       38",
"      </a>",
"      ] and are less likely to correctly interpret food labels [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adults with limited health literacy report lower rates of screening mammography and routine dental care [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among adults with HIV disease, those with limited health literacy were three times more likely to be non-adherent to their anti-retroviral medications [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Characteristics of healthcare systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that characteristics of health care systems and the behavior of health care providers may contribute to the problems experienced by those with limited literacy skills [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/42\">",
"     42",
"    </a>",
"    ]. Several factors within health care systems have been identified that contribute to poor healthcare delivery to this population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Worse health access: older people with a sixth-grade reading level or lower were twice as likely to have any of the three indicators of poor healthcare access (no",
"      <span class=\"nowrap\">",
"       doctor/regular",
"      </span>",
"      place of medical care, no flu shot, or no insurance for meds) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High patient concentration in healthcare systems serving patients with low health literacy; maldistribution of healthcare resources",
"     </li>",
"     <li>",
"      Undeveloped technology supports to enhance communication; reliance on single modes of communication (verbal, written)",
"     </li>",
"     <li>",
"      Insufficient training of the workforce",
"     </li>",
"     <li>",
"      Mismatch by culture",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      language between healthcare providers and patients",
"     </li>",
"     <li>",
"      Competing demands of multiple chronic conditions; lack of time; lack of incentives to providers",
"     </li>",
"     <li>",
"      Insufficient use of allied health professionals and teams; reliance on individual physicians",
"     </li>",
"     <li>",
"      System responds reactively rather than proactively; need for patients to be initiators and activators",
"     </li>",
"     <li>",
"      Inappropriate healthcare and communication objectives requiring mastery of complex self-care skills",
"     </li>",
"     <li>",
"      Lower health care expectations: parents with lower literacy reported higher satisfaction with pediatric care, explained by lower expectations and reluctance to be critical [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DETECTING LOW LITERACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of 'red flags' may help clinicians identify patients who may have limited literacy skills. Low literacy might be suspected for patients who:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do not know names of medications, or why they are being prescribed",
"     </li>",
"     <li>",
"      Are more passive in the clinical encounter and rarely ask questions",
"     </li>",
"     <li>",
"      Have difficulty completing forms",
"     </li>",
"     <li>",
"      Exhibit problems in navigating and completing diagnostic tests, procedures, medication refills,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      consultation processes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients with low literacy have told no one about their limitation, including family members. Patients may be reluctant to have their reading levels assessed and recorded in a clinical setting. Most patients with low literacy will overstate their level of reading competence.",
"   </p>",
"   <p>",
"    Nevertheless, most experts do not recommend routine screening to detect individuals with limited literacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/45\">",
"     45",
"    </a>",
"    ]. Evidence is insufficient that screening improved patient-clinician relationships or health outcomes, and most screening tools are too cumbersome or too imprecise [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several instruments have been studied, primarily for research purposes, to assess literacy levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. No screens are currently available to assess oral comprehension of medical information, an essential component of overall health literacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rapid screening instruments such as the",
"    <a class=\"external\" href=\"file://www.ahrq.gov/populations/sahlsatool.htm\">",
"     Rapid Estimate of Adult Literacy in Medicine (REALM)",
"    </a>",
"    can assess patient word recognition skills and provide an approximate grade level of reading ability in less than three minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/48\">",
"     48",
"    </a>",
"    ]. It correlates well with the Test of Functional Health Literacy of Adults (TOFHLA), a shortened version of the TOFHLA (S-TOFHLA), and other more sophisticated tests that take longer to administer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/49\">",
"     49",
"    </a>",
"    ]. Thus far, these have been used primarily for research; most experts do not advocate their use in clinical practice.",
"   </p>",
"   <p>",
"    Single item questions may be helpful in identifying patients with low literacy. A single screening question, \"How confident are you in filling out medical forms yourself?\", using \"somewhat\" or less as the cutpoint, performed well as a screening tool in Medicare and Veterans Administration (VA) populations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/46,52\">",
"     46,52",
"    </a>",
"    ]. The single question \"How often do you have someone help you read hospital materials?\" was effective in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/53\">",
"     53",
"    </a>",
"    ]. Another recent measure, the newest vital sign (NVS), is based on ability to read and correctly interpret a nutrition label [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/54\">",
"     54",
"    </a>",
"    ]. This method assesses a concrete health-related skill, and has been shown to correlate, in varying degrees, with direct health literacy measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/50,54\">",
"     50,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These self-report questions and the NVS may be useful to some clinicians. However, interventions to assist lower literacy individuals have been shown to benefit and be acceptable to those with adequate literacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/30,55\">",
"     30,55",
"    </a>",
"    ]. Therefore, it may be most helpful to adopt a \"universal\" approach to this issue, focused on making all health-related materials appropriate for those with limited health literacy, rather than focus on screening and targeted interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IMPROVING COMMUNICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that improving health communication is one means to improve quality of care, especially for those with limited literacy skills [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/42\">",
"     42",
"    </a>",
"    ]. A study of 800 patients in the US with diabetes found that patients with limited literacy were the most likely to report that improved clinician-patient communication would help them control their diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/56\">",
"     56",
"    </a>",
"    ]. Several strategies have been shown to improve communication for those with limited health literacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of plain language",
"     </li>",
"     <li>",
"      Use of concrete and specific phrases",
"     </li>",
"     <li>",
"      Use of multiple forms of communication, including written, oral, and visual",
"     </li>",
"     <li>",
"      Encouragement of questions from patients",
"     </li>",
"     <li>",
"      Confirmation of patient comprehension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Shared decision making can be a communication challenge for those with limited health literacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/58\">",
"     58",
"    </a>",
"    ]. One study suggested that participants with limited health literacy prefer less participatory decision making [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Health materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health materials such as patient discharge instructions, consent forms, education brochures, and contraception instructions are often written at levels that exceed the reading skills of many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/1\">",
"     1",
"    </a>",
"    ]. Most attention has centered upon simplifying written materials to improve knowledge [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/1,60\">",
"     1,60",
"    </a>",
"    ], but studies are needed to identify the best strategies to effectively communicate health information [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/61\">",
"     61",
"    </a>",
"    ]. Both higher and lower literacy patients prefer materials that are simple and direct. Use of videos, pictures, models, and toolkits may also be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/55,62\">",
"     55,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Oral comprehension",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to oral communication, patients with lower literacy, compared to those with higher literacy levels, ask fewer questions during a medical encounter, and are less likely to request additional services or more information [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians commonly use unclarified jargon terms during routine visits [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/64\">",
"     64",
"    </a>",
"    ]. Phrases such as \"your weight is stable\" or \"your sugars seem to show a wide range\" are easily misunderstood by patients. In a study of outpatient encounters among diabetes patients with limited literacy, clinicians were most likely to use jargon during critical points of the visit, such as during patient education, or while developing the treatment plan. Patients understood the terms less than 40 percent of the time, and clinicians' explanations of the jargon did not increase comprehension. In a companion study, clinicians caring for patients with limited literacy skills rarely confirmed patient comprehension of critical concepts (12 percent of concepts) and when they did, the patient misunderstood half the time [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/65\">",
"     65",
"    </a>",
"    ]. Moreover, among non-English-speaking patients, language and literacy may be negatively synergistic, especially among patients whose clinicians do not speak their primary language [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Numeracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research on the role of numeracy (literacy in numbers) and framing has revealed that most patients have very limited understanding of probability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/67\">",
"     67",
"    </a>",
"    ]. Limited numeracy can be found even with adequate health literacy, which in combination can still affect health [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Instruments are being developed that enable the patient to develop a clearer and more reliable understanding of the magnitude of benefit and toxicity related to treatment (eg, when eliciting patients' preference for adjuvant chemotherapy for cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Telling patients how many people would need treatment in order to see one person benefit (number needed to treat, NNT) may be helpful, although this has not been clearly proven. There is some evidence that patients find NNT as confusing a concept as other methods of risk communication [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/71\">",
"     71",
"    </a>",
"    ]. Experts have suggested that low numeracy provides challenges in self-management and decision-making, and that low numeracy may be a factor in health disparities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/72\">",
"     72",
"    </a>",
"    ]. Materials written for those with low numeracy have been shown to improve risk communication across all numeracy levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasingly, research suggests that low numeracy is associated with worse patient-centered outcomes. Among patients with diabetes, low numeracy was associated with lower self-efficacy, worse diabetes self-management, and, among insulin users, worse glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/74\">",
"     74",
"    </a>",
"    ]. Low numeracy was associated with increased asthma hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUGGESTIONS FOR PRACTICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review in 2004 found that studies were generally inadequate to draw definitive conclusions about the effectiveness of specific interventions for patients with low literacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/75\">",
"     75",
"    </a>",
"    ]. All patients, regardless of literacy level, benefit from clear communication, and many of the recommendations below are appropriate as \"universal precautions\" for all patients. Though widely promulgated by experts, the following strategies remain underutilized in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following suggestions are based upon our clinical experience and recommendations of other specialists [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/1,2,7,48,77-79\">",
"     1,2,7,48,77-79",
"    </a>",
"    ]; not all have been validated by formal study. Several interventions require action at the institutional or systems level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Assess literacy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ask patients about their educational attainment as part of their social history. Although associated with literacy, educational attainment is not a precise marker of literacy skills.",
"     </li>",
"     <li>",
"      Most patients overstate their literacy and are ashamed of this limitation. Promote a shame-free relationship in which questioning is encouraged [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/48\">",
"       48",
"      </a>",
"      ]. Encourage patients to come to visits with a companion or surrogate reader who can help reinforce the treatment plan.",
"     </li>",
"     <li>",
"      Be aware that clinicians tend to overestimate their patients' health literacy, especially among",
"      <span class=\"nowrap\">",
"       racial/ethnic",
"      </span>",
"      minority groups [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Teach about health literacy: medical students who learned about health literacy tend to communicate more clearly [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Communicate clearly",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Communicate clearly and confirm comprehension during critical communication events: transitions in care (eg, discharge), changes in clinical status (eg, new diagnosis), changes in treatments (eg, new medication with narrow therapeutic window), or critical tests or procedures (eg, biopsy for abnormal mammogram; colonoscopy for GI bleeding).",
"     </li>",
"     <li>",
"      Avoid using jargon. Be aware that jargon comes in several forms, such as technical jargon (eg, \"hemoglobin A1c\") or lay jargon (\"your weight is stable\"). Patients will only rarely disclose that they do not understand, so clinicians should use simple language. In one study, \"matching\" the patient's own language and vocabulary to communicate the clinician's message improved outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Use numbers clearly",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Express probabilities in terms of numbers rather than percentages (eg, '1 in 20' rather than '5 percent')",
"     </li>",
"     <li>",
"      Use multiple analogies to present risk",
"     </li>",
"     <li>",
"      Keep denominator consistent (eg, don't change between '1 in 10' and '12 in 100')",
"     </li>",
"     <li>",
"      Avoid relative risk ('Your risk will be three times higher') and instead use absolute risk ('Of 100 people who have this procedure, three will have pain lasting more than one month')",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Confirm comprehension",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ask all patients to bring in their medications to all appointments [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/35\">",
"       35",
"      </a>",
"      ]. Review medication lists routinely. Ask patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      What",
"      <span class=\"nowrap\">",
"       medicines/pills",
"      </span>",
"      do they actually take?",
"     </li>",
"     <li>",
"      How much and when do they take the medicines?",
"     </li>",
"     <li>",
"      What the medications are for?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use confirmatory, or \"teach back\" strategies to see whether patients understand instructions (",
"      <a class=\"graphic graphic_figure graphicRef61629 \" href=\"UTD.htm?4/6/4207\">",
"       figure 5",
"      </a>",
"      ). Ask them to restate in their own words what they have been told (eg, \"I want to make sure I was able to explain this to you clearly. Tell me how you will take this medication. Do you understand what this medication is for?\"). Use of \"teach-back\" does not increase visit length, and may be associated with better outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prioritize learning goals. Do not exceed 2 to 3 key concepts per visit. The communication approach \"teach-to-goal\", in which instruction continues until key learning goals are met, has been shown to be effective in asthma care [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/65,83\">",
"       65,83",
"      </a>",
"      ] and informed consent, and can disproportionately benefit those with limited literacy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Use appropriate educational materials",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review the reading materials that your office distributes. Materials at the eighth grade reading level or below, with a high ratio of pictures:text, are appropriate for most patient populations. (It should be noted that the patient information materials from UpToDate come in two varieties. Articles classified as &ldquo;Beyond the Basics&rdquo; are intentionally prepared for a higher literacy level, high school graduate and above, to fill a communication need for more educated patients. Articles classified as &ldquo;The Basics,&rdquo; meanwhile, are brief one to two page articles written in plain language and are designed to answer the most elemental questions on a given condition.)",
"     </li>",
"     <li>",
"      Do not expect reading materials to be effective in isolation. They are meant to reinforce verbal communications, and often require brief, in-person orientation to their goals and contents [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/55,84\">",
"       55,84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Make sure that informed consent and other important materials use plain English, preferably at the eighth grade level or below. Increasingly, accreditation bodies are encouraging and even requiring such documents be used.",
"     </li>",
"     <li>",
"      Consider use of videos, audiotapes, models, and pictures. Visual aids are helpful to many patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/33\">",
"       33",
"      </a>",
"      ]. A recent RCT of a visual medication schedule in an anticoagulation clinic demonstrated dramatic reductions in time to achieving optimal anticoagulant control, an effect seen across literacy levels [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/85\">",
"       85",
"      </a>",
"      ]. Patients with limited literacy preferred an interactive computer program which allows iterative explanations without time constraints rather than a person explaining medical documents [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Use appropriate resources",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use a multi-disciplinary approach for patient care, and reinforce complex information through",
"      <span class=\"nowrap\">",
"       nursing/pharmacy",
"      </span>",
"      and other staff. Pharmacists play a crucial role in conveying not only medication names, but instructions [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/87\">",
"       87",
"      </a>",
"      ]. Consider enrolling patients in self-management support programs that do not involve the internet; telephone programs are cost-effective [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/88\">",
"       88",
"      </a>",
"      ]. Patients with limited literacy skills are most likely to enroll in such programs [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/56\">",
"       56",
"      </a>",
"      ] and derive benefit from them [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/88-90\">",
"       88-90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consider referral to a local literacy organization, often available at the public library. Depression outcomes were significantly improved when lower literacy patients were provided with a referral to a literacy class as an adjunct to usual depression care [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In certain cases, especially when education exceeds the expected level of literacy, consider referral for neuro-psychiatric testing for possible learning disabilities or other cognitive disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     HEALTH LITERACY INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A host of interventions have been developed, with varying results, to improve care among populations with limited health literacy. Selected examples follow:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A self-management support intervention for type 2 diabetes patients with limited health literacy used automated telephone technology with care manager follow-up. This model showed improvements in interpersonal process of care, self management behaviors, and a decrease in bed days per month compared to the control group [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A literacy and numeracy focused diabetes self-management program resulted in short-term, but not sustained, improvement in glycemic control [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A health care provider-directed intervention focused on limited-literacy patients successfully increased colorectal cancer screening rates [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Literacy education improved self efficacy and decreased depressive symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/95\">",
"       95",
"      </a>",
"      ]; literacy education provided along with standard depression treatment could decrease depression symptoms to a greater extent than standard treatment alone [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At an urban safety-net hospital, using a nurse directed patient education intervention with limited-literacy-appropriate materials and telephone follow-up decreased emergency department visits and hospital readmission rates [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a systematic review of health literacy interventions, the most likely patient-centered outcomes to improve were self-efficacy and knowledge [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There is a growing appreciation that healthcare organizations should adopt system-wide strategies to reduce the literacy demand of healthcare. Such strategies make effective patient communication a priority across all levels of the organization and across all communication channels [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A compilation of resources is available through the Society of General Internal Medicine Health Literacy Interest Group [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/99\">",
"       99",
"      </a>",
"      ] and through the",
"      <a class=\"external\" href=\"file://nnlm.gov/sea/outreach/healthlitkit/bibliography.html\">",
"       National Network of Libraries of Medicine",
"      </a>",
"      . This reference includes links to common screening instruments and to \"easy-to-read\" materials.",
"     </li>",
"     <li>",
"      The US Department of Health and Human Services established the",
"      <a class=\"external\" href=\"file://www.health.gov/communication/hlactionplan/\">",
"       National Action Plan",
"      </a>",
"      in 2010, which suggests goals and strategies to improve health literacy.",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/\">",
"       Medline Plus",
"      </a>",
"      is a resource for online patient educational materials from a variety of nonprofit sources. Appropriate materials are marked \"easy to read\" or \"Spanish.\"",
"     </li>",
"     <li>",
"      The Agency for Healthcare Research and Quality",
"      <a class=\"external\" href=\"file://www.ahrq.gov/qual/literacy/\">",
"       Universal Precautions for Health Literacy",
"      </a>",
"      toolkit is designed to help adult and pediatric practices ensure that systems are in place to promote better understanding by all patients.",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www.ama-assn.org/ama/pub/about-ama/ama-foundation/our-programs/public-health/health-literacy-program/health-literacy-video.page\">",
"       American Medical Association",
"      </a>",
"      has developed two videos on health literacy intended for physicians and their staff to help patients with limited health literacy.",
"     </li>",
"     <li>",
"      The Institute of Medicine&rsquo;s Health Literacy Round Table describes the attributes of a health literate organization, with specific organizational strategies to address the needs of limited health literacy populations [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17609/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    The Patient Information Table of Contents can be accessed here:",
"    <a class=\"external\" href=\"file://www.uptodate.com/online/content/toc.do?tocKey=table_of_contents/12\">",
"     file://www.uptodate.com/online/content/toc.do?tocKey=table_of_contents/12",
"    </a>",
"    . You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effective healthcare relies on the ability to communicate with patients. Low literacy and poor comprehension are common and unlikely to be acknowledged by patients. Low health literacy may be found in patients with adequate general literacy, but has the most impact on those with limited literacy. Low literacy is more common in people over age 65, without a high school education, members of minority population groups or immigrants, and with chronic diseases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low literacy is associated with poorer health outcomes, lower patient satisfaction with care, worse patient safety, and higher health costs. Low literacy impacts a patient's ability to take medications appropriately, navigate the health care system, and affects ethical issues such as informed consent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Significance and impact'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most experts do not recommend routine screening to detect limited literacy, but advocate system-wide improvements to improve communication for all patients. However, certain \"red flags\" may raise concern about literacy in patients: difficulty with medications, follow-through with tests, passivity during the exam, and trouble completing forms. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Detecting low literacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many suggestions for improving care for patients with limited literacy would provide benefit for all patients. Suggestions include promoting a shame-free relationship, avoiding jargon and confirming comprehension, prioritizing learning goals, using appropriate written and multimedia patient education materials to reinforce (but not substitute for) oral communication, and involving multidisciplinary teams and community resources for patients with low literacy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Suggestions for practice'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors wish to acknowledge Devorah B Keller, MD, MPH and Andrea Lopez, BS, who assisted in the preparation of this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/1\">",
"      Health literacy: report of the Council on Scientific Affairs. Ad Hoc Committee on Health Literacy for the Council on Scientific Affairs, American Medical Association. JAMA 1999; 281:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/2\">",
"      Weiss BD, Coyne C. Communicating with patients who cannot read. N Engl J Med 1997; 337:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/3\">",
"      Kefalides PT. Illiteracy: the silent barrier to health care. Ann Intern Med 1999; 130:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/4\">",
"      Kripalani, S, Paasche-Orlow, MK, Parker, RM, Saha, S. Advancing the field of health literacy. J Gen Intern Med 2006; 21:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/5\">",
"      Paasche-Orlow MK, Parker RM, Gazmararian JA, et al. The prevalence of limited health literacy. J Gen Intern Med 2005; 20:175.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. IOM report 2004. www.iom.edu (Accessed on January 11, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/7\">",
"      Paasche-Orlow MK, Schillinger D, Greene SM, Wagner EH. How health care systems can begin to address the challenge of limited literacy. J Gen Intern Med 2006; 21:884.",
"     </a>",
"    </li>",
"    <li>",
"     file://nces.ed.gov/naal (Accessed on January 08, 2001).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/9\">",
"      Rudd RE. Health literacy skills of U.S. adults. Am J Health Behav 2007; 31 Suppl 1:S8.",
"     </a>",
"    </li>",
"    <li>",
"     \"What did the doctor say?\": Improving health literacy to protect patient safety. JCAHO 2007. Available at: www.jointcommission.org/NewsRoom/PressKits/Health_Literacy (Accessed on January 08, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/11\">",
"      Gazmararian JA, Baker DW, Williams MV, et al. Health literacy among Medicare enrollees in a managed care organization. JAMA 1999; 281:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/12\">",
"      Parker RM, Wolf MS, Kirsch I. Preparing for an epidemic of limited health literacy: weathering the perfect storm. J Gen Intern Med 2008; 23:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/13\">",
"      Paasche-Orlow MK, Wolf MS. The causal pathways linking health literacy to health outcomes. Am J Health Behav 2007; 31 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/14\">",
"      von Wagner C, Steptoe A, Wolf MS, Wardle J. Health literacy and health actions: a review and a framework from health psychology. Health Educ Behav 2009; 36:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/15\">",
"      Weiss BD, Blanchard JS, McGee DL, et al. Illiteracy among Medicaid recipients and its relationship to health care costs. J Health Care Poor Underserved 1994; 5:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/16\">",
"      Schillinger D, Grumbach K, Piette J, et al. Association of health literacy with diabetes outcomes. JAMA 2002; 288:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/17\">",
"      Wolf MS, Gazmararian JA, Baker DW. Health literacy and functional health status among older adults. Arch Intern Med 2005; 165:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/18\">",
"      Peterson PN, Shetterly SM, Clarke CL, et al. Health literacy and outcomes among patients with heart failure. JAMA 2011; 305:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/19\">",
"      Berkman ND, Sheridan SL, Donahue KE, et al. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med 2011; 155:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/20\">",
"      Bostock S, Steptoe A. Association between low functional health literacy and mortality in older adults: longitudinal cohort study. BMJ 2012; 344:e1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/21\">",
"      Sudore RL, Yaffe K, Satterfield S, et al. Limited literacy and mortality in the elderly: the health, aging, and body composition study. J Gen Intern Med 2006; 21:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/22\">",
"      Baker DW, Wolf MS, Feinglass J, Thompson JA. Health literacy, cognitive abilities, and mortality among elderly persons. J Gen Intern Med 2008; 23:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/23\">",
"      Baker DW, Wolf MS, Feinglass J, et al. Health literacy and mortality among elderly persons. Arch Intern Med 2007; 167:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/24\">",
"      Bennett IM, Culhane JF, McCollum KF, et al. Literacy and depressive symptomatology among pregnant Latinas with limited English proficiency. Am J Orthopsychiatry 2007; 77:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/25\">",
"      DeWalt DA, Dilling MH, Rosenthal MS, Pignone MP. Low parental literacy is associated with worse asthma care measures in children. Ambul Pediatr 2007; 7:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/26\">",
"      Gordon EJ, Wolf MS. Health literacy skills of kidney transplant recipients. Prog Transplant 2009; 19:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/27\">",
"      Cho YI, Lee SY, Arozullah AM, Crittenden KS. Effects of health literacy on health status and health service utilization amongst the elderly. Soc Sci Med 2008; 66:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/28\">",
"      Howard DH, Gazmararian J, Parker RM. The impact of low health literacy on the medical costs of Medicare managed care enrollees. Am J Med 2005; 118:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/29\">",
"      Schillinger D, Bindman A, Wang F, et al. Functional health literacy and the quality of physician-patient communication among diabetes patients. Patient Educ Couns 2004; 52:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/30\">",
"      Sudore RL, Landefeld CS, Williams BA, et al. Use of a modified informed consent process among vulnerable patients: a descriptive study. J Gen Intern Med 2006; 21:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/31\">",
"      Williams MV, Baker DW, Parker RM, Nurss JR. Relationship of functional health literacy to patients' knowledge of their chronic disease. A study of patients with hypertension and diabetes. Arch Intern Med 1998; 158:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/32\">",
"      Fang MC, Machtinger EL, Wang F, Schillinger D. Health literacy and anticoagulation-related outcomes among patients taking warfarin. J Gen Intern Med 2006; 21:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/33\">",
"      Schillinger D, Machtinger EL, Wang F, et al. Language, literacy, and communication regarding medication in an anticoagulation clinic: a comparison of verbal vs. visual assessment. J Health Commun 2006; 11:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/34\">",
"      Schillinger D, Wang F, Rodriguez M, et al. The importance of establishing regimen concordance in preventing medication errors in anticoagulant care. J Health Commun 2006; 11:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/35\">",
"      Persell SD, Osborn CY, Richard R, et al. Limited health literacy is a barrier to medication reconciliation in ambulatory care. J Gen Intern Med 2007; 22:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/36\">",
"      Davis TC, Wolf MS, Bass PF 3rd, et al. Literacy and misunderstanding prescription drug labels. Ann Intern Med 2006; 145:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/37\">",
"      Wolf MS, Davis TC, Tilson HH, et al. Misunderstanding of prescription drug warning labels among patients with low literacy. Am J Health Syst Pharm 2006; 63:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/38\">",
"      Huizinga MM, Carlisle AJ, Cavanaugh KL, et al. Literacy, numeracy, and portion-size estimation skills. Am J Prev Med 2009; 36:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/39\">",
"      Rothman RL, Housam R, Weiss H, et al. Patient understanding of food labels: the role of literacy and numeracy. Am J Prev Med 2006; 31:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/40\">",
"      Bennett IM, Chen J, Soroui JS, White S. The contribution of health literacy to disparities in self-rated health status and preventive health behaviors in older adults. Ann Fam Med 2009; 7:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/41\">",
"      Wolf MS, Davis TC, Osborn CY, et al. Literacy, self-efficacy, and HIV medication adherence. Patient Educ Couns 2007; 65:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/42\">",
"      Schillinger D. Literacy and health communication: reversing the 'inverse care law'. Am J Bioeth 2007; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/43\">",
"      Sudore RL, Mehta KM, Simonsick EM, et al. Limited literacy in older people and disparities in health and healthcare access. J Am Geriatr Soc 2006; 54:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/44\">",
"      Rosenthal MS, Socolar RR, DeWalt DA, et al. Parents with low literacy report higher quality of parent-provider relationships in a residency clinic. Ambul Pediatr 2007; 7:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/45\">",
"      Seligman HK, Wang FF, Palacios JL, et al. Physician notification of their diabetes patients' limited health literacy. A randomized, controlled trial. J Gen Intern Med 2005; 20:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/46\">",
"      Wallace LS, Rogers ES, Roskos SE, et al. Brief report: screening items to identify patients with limited health literacy skills. J Gen Intern Med 2006; 21:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/47\">",
"      Wolf MS, Davis TC, Parker RM. Editorial: the emerging field of health literacy research. Am J Health Behav 2007; 31 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/48\">",
"      Doak CC, Doak LG, Friedell GH, Meade CD. Improving comprehension for cancer patients with low literacy skills: strategies for clinicians. CA Cancer J Clin 1998; 48:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/49\">",
"      Parker RM, Baker DW, Williams MV, Nurss JR. The test of functional health literacy in adults: a new instrument for measuring patients' literacy skills. J Gen Intern Med 1995; 10:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/50\">",
"      Osborn CY, Weiss BD, Davis TC, et al. Measuring adult literacy in health care: performance of the newest vital sign. Am J Health Behav 2007; 31 Suppl 1:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/51\">",
"      Baker DW. The meaning and the measure of health literacy. J Gen Intern Med 2006; 21:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/52\">",
"      Chew LD, Griffin JM, Partin MR, et al. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med 2008; 23:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/53\">",
"      Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. Fam Med 2004; 36:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/54\">",
"      Weiss BD, Mays MZ, Martz W, et al. Quick assessment of literacy in primary care: the newest vital sign. Ann Fam Med 2005; 3:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/55\">",
"      Sudore RL, Landefeld CS, Barnes DE, et al. An advance directive redesigned to meet the literacy level of most adults: a randomized trial. Patient Educ Couns 2007; 69:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/56\">",
"      Sarkar U, Piette JD, Gonzales R, et al. Preferences for self-management support: findings from a survey of diabetes patients in safety-net health systems. Patient Educ Couns 2008; 70:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/57\">",
"      Hironaka LK, Paasche-Orlow MK. The implications of health literacy on patient-provider communication. Arch Dis Child 2008; 93:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/58\">",
"      McCaffery KJ, Smith SK, Wolf M. The challenge of shared decision making among patients with lower literacy: a framework for research and development. Med Decis Making 2010; 30:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/59\">",
"      DeWalt DA, Boone RS, Pignone MP. Literacy and its relationship with self-efficacy, trust, and participation in medical decision making. Am J Health Behav 2007; 31 Suppl 1:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/60\">",
"      Jolly BT, Scott JL, Sanford SM. Simplification of emergency department discharge instructions improves patient comprehension. Ann Emerg Med 1995; 26:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/61\">",
"      Schillinger D. Misunderstanding prescription labels: the genie is out of the bottle. Ann Intern Med 2006; 145:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/62\">",
"      Wolff K, Cavanaugh K, Malone R, et al. The Diabetes Literacy and Numeracy Education Toolkit (DLNET): materials to facilitate diabetes education and management in patients with low literacy and numeracy skills. Diabetes Educ 2009; 35:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/63\">",
"      Katz MG, Jacobson TA, Veledar E, Kripalani S. Patient literacy and question-asking behavior during the medical encounter: a mixed-methods analysis. J Gen Intern Med 2007; 22:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/64\">",
"      Castro CM, Wilson C, Wang F, Schillinger D. Babel babble: physicians' use of unclarified medical jargon with patients. Am J Health Behav 2007; 31 Suppl 1:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/65\">",
"      Schillinger D, Piette J, Grumbach K, et al. Closing the loop: physician communication with diabetic patients who have low health literacy. Arch Intern Med 2003; 163:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/66\">",
"      Sudore RL, Landefeld CS, P&eacute;rez-Stable EJ, et al. Unraveling the relationship between literacy, language proficiency, and patient-physician communication. Patient Educ Couns 2009; 75:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/67\">",
"      Schwartz LM, Woloshin S, Black WC, Welch HG. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med 1997; 127:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/68\">",
"      Apter AJ, Paasche-Orlow MK, Remillard JT, et al. Numeracy and communication with patients: they are counting on us. J Gen Intern Med 2008; 23:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/69\">",
"      Levine MN, Gafni A, Markham B, MacFarlane D. A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med 1992; 117:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/70\">",
"      Zikmund-Fisher BJ, Smith DM, Ubel PA, Fagerlin A. Validation of the Subjective Numeracy Scale: effects of low numeracy on comprehension of risk communications and utility elicitations. Med Decis Making 2007; 27:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/71\">",
"      Halvorsen PA, Kristiansen IS. Decisions on drug therapies by numbers needed to treat: a randomized trial. Arch Intern Med 2005; 165:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/72\">",
"      Montori VM, Rothman RL. Weakness in numbers. The challenge of numeracy in health care. J Gen Intern Med 2005; 20:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/73\">",
"      Woloshin S, Schwartz LM, Welch HG. The effectiveness of a primer to help people understand risk: two randomized trials in distinct populations. Ann Intern Med 2007; 146:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/74\">",
"      Cavanaugh K, Huizinga MM, Wallston KA, et al. Association of numeracy and diabetes control. Ann Intern Med 2008; 148:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/75\">",
"      Pignone M, DeWalt DA, Sheridan S, et al. Interventions to improve health outcomes for patients with low literacy. A systematic review. J Gen Intern Med 2005; 20:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/76\">",
"      Schwartzberg JG, Cowett A, VanGeest J, Wolf MS. Communication techniques for patients with low health literacy: a survey of physicians, nurses, and pharmacists. Am J Health Behav 2007; 31 Suppl 1:S96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/77\">",
"      Mayeaux EJ Jr, Murphy PW, Arnold C, et al. Improving patient education for patients with low literacy skills. Am Fam Physician 1996; 53:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/78\">",
"      Fagerlin A, Ubel PA, Smith DM, Zikmund-Fisher BJ. Making numbers matter: present and future research in risk communication. Am J Health Behav 2007; 31 Suppl 1:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/79\">",
"      Gordon EJ, Wolf MS. Beyond the basics: designing a comprehensive response to low health literacy. Am J Bioeth 2007; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/80\">",
"      Kelly PA, Haidet P. Physician overestimation of patient literacy: a potential source of health care disparities. Patient Educ Couns 2007; 66:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/81\">",
"      Harper W, Cook S, Makoul G. Teaching medical students about health literacy: 2 Chicago initiatives. Am J Health Behav 2007; 31 Suppl 1:S111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/82\">",
"      Williams N, Ogden J. The impact of matching the patient's vocabulary: a randomized control trial. Fam Pract 2004; 21:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/83\">",
"      Paasche-Orlow MK, Riekert KA, Bilderback A, et al. Tailored education may reduce health literacy disparities in asthma self-management. Am J Respir Crit Care Med 2005; 172:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/84\">",
"      Seligman HK, Wallace AS, DeWalt DA, et al. Facilitating behavior change with low-literacy patient education materials. Am J Health Behav 2007; 31 Suppl 1:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/85\">",
"      Machtinger EL, Wang F, Chen LL, et al. A visual medication schedule to improve anticoagulation control: a randomized, controlled trial. Jt Comm J Qual Patient Saf 2007; 33:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/86\">",
"      Bickmore TW, Pfeifer LM, Paasche-Orlow MK. Using computer agents to explain medical documents to patients with low health literacy. Patient Educ Couns 2009; 75:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/87\">",
"      Brown L, Upchurch G, Frank SK. Low health literacy: what pharmacists can do to help. J Am Pharm Assoc (2003) 2006; 46:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/88\">",
"      Schillinger D, Hammer H, Wang F, et al. Seeing in 3-D: examining the reach of diabetes self-management support strategies in a public health care system. Health Educ Behav 2008; 35:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/89\">",
"      DeWalt DA, Malone RM, Bryant ME, et al. A heart failure self-management program for patients of all literacy levels: a randomized, controlled trial [ISRCTN11535170]. BMC Health Serv Res 2006; 6:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/90\">",
"      Rothman RL, DeWalt DA, Malone R, et al. Influence of patient literacy on the effectiveness of a primary care-based diabetes disease management program. JAMA 2004; 292:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/91\">",
"      Weiss BD, Francis L, Senf JH, et al. Literacy education as treatment for depression in patients with limited literacy and depression: a randomized controlled trial. J Gen Intern Med 2006; 21:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/92\">",
"      Schillinger D, Handley M, Wang F, Hammer H. Effects of self-management support on structure, process, and outcomes among vulnerable patients with diabetes: a three-arm practical clinical trial. Diabetes Care 2009; 32:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/93\">",
"      Cavanaugh K, Wallston KA, Gebretsadik T, et al. Addressing literacy and numeracy to improve diabetes care: two randomized controlled trials. Diabetes Care 2009; 32:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/94\">",
"      Ferreira MR, Dolan NC, Fitzgibbon ML, et al. Health care provider-directed intervention to increase colorectal cancer screening among veterans: results of a randomized controlled trial. J Clin Oncol 2005; 23:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/95\">",
"      Francis L, Weiss BD, Senf JH, et al. Does literacy education improve symptoms of depression and self-efficacy in individuals with low literacy and depressive symptoms? A preliminary investigation. J Am Board Fam Med 2007; 20:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/96\">",
"      Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med 2009; 150:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17609/abstract/97\">",
"      Clement S, Ibrahim S, Crichton N, et al. Complex interventions to improve the health of people with limited literacy: A systematic review. Patient Educ Couns 2009; 75:340.",
"     </a>",
"    </li>",
"    <li>",
"     Schillinger D, Keller D. The Other Side of the Coin: Attributes of a Health Literate Healthcare Organization. Institute of Medicine (IOM), Roundtable on Health Literacy 2011. Available at: file://www.iom.edu/~/media/Files/Activity%20Files/PublicHealth/HealthLiteracy/2011-NOV-16/Commissioned%20Paper.pdf (Accessed on April 23, 2012).",
"    </li>",
"    <li>",
"     Health Literacy for the Clinician Educator (SGIM 2008, workshop WA04). file://www.sgim.org/userfiles/file/AMHandouts/AM08/WA04%20Harper.pdf (Accessed on May 31, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2766 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-85B74C0F79-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17609=[""].join("\n");
var outline_f17_12_17609=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SIGNIFICANCE AND IMPACT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Poor health knowledge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Characteristics of healthcare systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DETECTING LOW LITERACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IMPROVING COMMUNICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Health materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oral comprehension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Numeracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUGGESTIONS FOR PRACTICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Assess literacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Communicate clearly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Use numbers clearly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Confirm comprehension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Use appropriate educational materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Use appropriate resources",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HEALTH LITERACY INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2766\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2766|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/57/12190\" title=\"figure 1\">",
"      Health literacy level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/21/44382\" title=\"figure 2\">",
"      Health literacy assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/53/14160\" title=\"figure 3\">",
"      Literacy by education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/37/21086\" title=\"figure 4\">",
"      Literacy by insurance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/6/4207\" title=\"figure 5\">",
"      Communication loop",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24537?source=related_link\">",
"      Cross-cultural care and communication",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_12_17610="Medical complications of stroke";
var content_f17_12_17610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical complications of stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/12/17610/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17610/contributors\">",
"     Teresa L Jacobs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/12/17610/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17610/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/12/17610/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/12/17610/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/12/17610/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical complications of acute ischemic stroke are common and often lead to poor clinical outcomes. The frequency of medical complications must be recognized so that preventive strategies and appropriate treatment are employed.",
"   </p>",
"   <p>",
"    The major medical complications associated with stroke will be reviewed here. Cardiac and pulmonary complications of stroke and poststroke seizures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26952?source=see_link\">",
"     \"Cardiac complications of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10087?source=see_link\">",
"     \"Stroke-related pulmonary complications and abnormal respiratory patterns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Post-stroke seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rates of reported medical complications of stroke are high (",
"    <a class=\"graphic graphic_table graphicRef52076 \" href=\"UTD.htm?20/49/21275\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In a prospective study that analyzed the placebo group of the Randomized Trial of Tirilazad Mesylate in Acute Stroke (RANTTAS) database (n = 279), at least one medical complication occurred in 95 percent of patients, and at least one serious medical complication (defined as prolonged, immediately life threatening, or resulting in hospitalization or death) occurred in 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/2\">",
"     2",
"    </a>",
"    ]. The most common serious medical complications were pneumonia (5 percent), gastrointestinal bleeding (3 percent), congestive heart failure (3 percent), and cardiac arrest (2 percent) (",
"    <a class=\"graphic graphic_table graphicRef68148 \" href=\"UTD.htm?10/49/11036\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Approximately 50 percent of deaths after stroke are attributed to medical complications. Prospectively collected data suggest that direct effects of ischemic stroke account for the majority of deaths within the first week after stroke, but medical complications predominately account for the mortality thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In support of these observations, an autopsy series found that the most common cause of death after ischemic and hemorrhagic stroke was cerebrovascular disease in the first week, pulmonary embolism in the second through fourth weeks, bronchopneumonia in the second and third months, and cardiac disease after three months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, a single-center prospective study found that patients who experienced in-hospital medical complications after acute ischemic stroke had significantly higher mortality rates even four years after stroke onset [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/7\">",
"     7",
"    </a>",
"    ]. Older age, atrial fibrillation, and greater disability at discharge were associated with increased mortality after one year in survivors.",
"   </p>",
"   <p>",
"    Good general care should be directed at maintaining vital cardiopulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/8\">",
"     8",
"    </a>",
"    ]. Measures to prevent subacute complications of stroke (aspiration, malnutrition, pneumonia, deep vein thrombosis, pulmonary embolism, pressure sores, orthopedic complications, and contractures) are recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VENOUS THROMBOEMBOLISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep vein thrombosis (DVT) is a serious problem for patients with stroke because it may lead to life-threatening pulmonary embolism (PE) (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Pulmonary embolism'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The overall prevalence of clinically evident DVT after acute stroke is 2 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. The prevalence of asymptomatic DVT is even higher. In the largest observational report, which evaluated 5632 immobile patients with acute stroke using duplex ultrasound, DVT was detected within 10 days of enrollment in 11 percent, and within 30 days in 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/13\">",
"     13",
"    </a>",
"    ]. A smaller study using MRI in patients with acute stroke reported proximal DVT at 21 days in 18 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DVT development may occur as early as the second day and has a peak incidence between two to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/14\">",
"     14",
"    </a>",
"    ]. The risk of death associated with an untreated proximal DVT in patients with stroke is about 15 percent.",
"   </p>",
"   <p>",
"    Patients with hemiparesis are predisposed to DVT development, and the degree of paresis confers a graded risk of DVT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/15\">",
"     15",
"    </a>",
"    ]. In a report that included 542 patients with DVT and a weak leg, the DVT was ipsilateral to the weak leg in 73 percent, contralateral in 11 percent, and bilateral in 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, the presence of a DVT on the nonparetic side suggests the presence of DVT on the paretic side [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional important risk factors for DVT include advanced age, high stroke severity, immobility, and atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/12,16\">",
"     12,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most circumstances, compression ultrasonography is the noninvasive test of choice for the diagnosis of patients with suspected DVT. The evaluation of patients with suspected DVT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary embolism (PE), often unassociated with clinically recognized DVT, accounts for 13 to 25 percent of early deaths after stroke and is the most common cause of death at its peak occurrence about two to four weeks after stroke onset [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/14\">",
"     14",
"    </a>",
"    ]. The incidence of PE in the first few months after stroke ranges from 1 to 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/1,2,9-11,17\">",
"     1,2,9-11,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     VTE prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for the prevention of venous thromboembolism (VTE) in patients with acute ischemic stroke include anticoagulants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and intermittent pneumatic compression devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective studies have established that both unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and low molecular weight heparin (LMWH) are effective in reducing DVT and PE in patients with stroke, at the price of an increased risk of intracerebral and extracranial bleeding when compared with no anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Thus, the benefit-to-risk ratio is less certain in patients with acute stroke.",
"   </p>",
"   <p>",
"    The following reports convey the range of observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2007 systematic review of randomized controlled trials comparing early (typically within 48 hours) administration of either LMWH or unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      with control (placebo or no treatment) for VTE prevention in patients with acute ischemic stroke, 16 trials published through January 2005 involving 23,043 patients met the inclusion criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/20\">",
"       20",
"      </a>",
"      ]. However, the number of events was small and different doses of anticoagulant treatment were used, precluding definitive conclusions. Most of the patients (over 19,000) in the meta-analysis came from the IST study [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/11\">",
"       11",
"      </a>",
"      ], in which VTE was a secondary outcome. The following outcomes were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/20\">",
"       20",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low-dose unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (&le;15,000",
"      <span class=\"nowrap\">",
"       units/day)",
"      </span>",
"      decreased the risk of DVT (odds ratio [OR] 0.17, 95% CI 0.11-0.26), but had no significant effect on the risk of PE (OR 0.83, 95% CI 0.53-1.31) and no significant effect on the risk of major intracranial or extracranial hemorrhage.",
"     </li>",
"     <li>",
"      High-dose unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (&gt;15,000",
"      <span class=\"nowrap\">",
"       units/day)",
"      </span>",
"      was associated with a reduced risk of PE (OR 0.49, 95% CI 0.29-0.83), but an increased risk of both major intracranial hemorrhage (OR 3.86, 95% CI 2.41-6.19) and extracranial hemorrhage (OR 4.74, 95% CI 2.88-7.78). None of the trials evaluated the risk of DVT with high-dose heparin.",
"     </li>",
"     <li>",
"      Low-dose LMWH (&le;6000 international",
"      <span class=\"nowrap\">",
"       units/day,",
"      </span>",
"      or a weight-adjusted dose of &le;86 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per day) was associated with a reduced risk of both DVT (OR 0.34, 95% CI 0.19-0.59) and PE (OR 0.36, 95% CI 0.15-0.87), with no increased risk of major intracranial or extracranial hemorrhage.",
"     </li>",
"     <li>",
"      High-dose LMWH (&gt;6000 international",
"      <span class=\"nowrap\">",
"       units/day",
"      </span>",
"      or &gt;86 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per day) was associated with a decreased risk of both DVT (OR 0.07, 95% CI 0.02-0.29) and PE (OR 0.44, 95% CI 0.18-1.11), an increased risk of major intracranial hemorrhage (OR 2.01, 95% CI 1.02-3.96), and a trend toward an increased risk of extracranial hemorrhage (OR 1.78, 95% CI 0.99-3.17).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that low-dose LMWH offered the best benefit-to-risk ratio for VTE prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/20\">",
"     20",
"    </a>",
"    ]. The number needed to treat with low-dose LMWH to prevent DVT and PE was 7 and 38, respectively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of three randomized trials with over 2,000 patients who had ischemic stroke, LMWHs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      in two trials and certoparin in one trial) were superior to unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      for the prevention of any VTE (odds ratio [OR] 0.54, 95% CI 0.41-0.70) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/21\">",
"       21",
"      </a>",
"      ]. In addition, LMWH use resulted in a reduction of PE (OR 0.26, 95% CI 0.07-0.95), though the number of events was small. There was no significant difference between groups for rates of intracerebral hemorrhage, overall bleeding, or mortality. Nearly two-thirds of the patients in the meta-analysis came from the open-label PREVAIL trial [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anticoagulants should not be used for 24 hours after the administration of thrombolytic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90846593\">",
"    <span class=\"h3\">",
"     Intermittent pneumatic compression",
"    </span>",
"   </p>",
"   <p>",
"    Intermittent pneumatic compression (IPC) has virtually no clinically important side effects and may be useful in patients who have a high risk of bleeding. The 2012 ACCP guidelines note that there is only low-quality direct evidence supporting the use of IPC in patients with stroke and impaired mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the ACCP found higher-quality evidence from other populations, mainly postoperative patients, showing that IPC was associated with reduction in DVT of approximately 50 percent compared with no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IPC is contraindicated in those with overt evidence of leg ischemia caused by peripheral vascular disease, and it is also contraindicated in those at bed rest or immobilized for more than 72 hours without any form of pharmacologic prophylaxis, since it may cause a newly formed clot to dislodge. Less than total compliance by patients and caregivers can also limit the effectiveness of IPC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H27#H27\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Intermittent pneumatic compression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90846716\">",
"    <span class=\"h3\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In medical patients considered at high risk,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    decreases the frequency of VTE compared with placebo or no treatment, but the degree of reduction is less than that obtained using anticoagulants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link&amp;anchor=H22#H22\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a separate indication, early",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy is recommended for most patients with acute ischemic stroke or TIA who are not receiving oral anticoagulants because it reduces the risk of early recurrent stroke or death. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=see_link&amp;anchor=H5#H5\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\", section on 'Early aspirin use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90846504\">",
"    <span class=\"h3\">",
"     Graduated compression stockings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graduated compression stockings are not beneficial and may be harmful in the setting of acute stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/25\">",
"     25",
"    </a>",
"    ]. In the randomized controlled CLOTS 1 trial that evaluated 2158 patients within one week of acute stroke, thigh-length graduated compression stockings did",
"    <strong>",
"     not",
"    </strong>",
"    reduce occurrence of symptomatic or asymptomatic proximal DVT (the primary outcome) or VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/26\">",
"     26",
"    </a>",
"    ]. However, skin lesions (breaks, ulcers, blisters and necrosis) were significantly more common in patients assigned to graduated compression stockings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several evidence-based clinical guidelines support the use of subcutaneous anticoagulants (eg, low-dose unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , LMWH) or intermittent pneumatic compression to prevent DVT and PE in patients with acute ischemic stroke who have restricted mobility, unless the assessed risk for bleeding is greater than the risk of thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/8,23,27\">",
"     8,23,27",
"    </a>",
"    ]. As an example, the 2012 ACCP guidelines suggest subcutaneous heparin, LMWH, or intermittent pneumatic compression over no prophylaxis, and further suggest LMWH over unfractionated heparin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the evidence presented above and the lack of definitive trials, we suggest VTE prophylaxis using either subcutaneous LMWH (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40 mg daily) or subcutaneous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    5000 units two to three times daily for patients with acute ischemic stroke who have restricted mobility. This recommendation applies only to patients for whom the assessed benefit of VTE prophylaxis is thought to outweigh the risk of bleeding. In addition, we suggest the combined use of intermittent pneumatic compression with prophylactic anticoagulation for all patients with restricted mobility.",
"   </p>",
"   <p>",
"    VTE prophylaxis in patients with acute intracerebral hemorrhage (ICH) or prior ICH is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=see_link&amp;anchor=H5#H5\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\", section on 'Prevention of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal duration of VTE prophylaxis is uncertain, as the clinical trials have generally employed prophylaxis for two weeks, and longer periods of treatment are not well studied in patients with stroke. However, long-term prophylaxis in immobilized patients may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/28\">",
"     28",
"    </a>",
"    ]. The 2012 ACCP guidelines state that VTE prophylaxis should be initiated as early as possible and be continued during hospitalization or until the patient regains mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     VTE treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    and LMWH are effective for reducing the rate of fatal and nonfatal PE in patients without stroke who have proximal DVT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PE. Consequently, heparin, LMWH, or heparinoid, followed by oral anticoagulation for three months may be beneficial in patients with acute stroke. Inferior vena cava (IVC) filters are an alternative in this situation. Embolectomy and thrombolysis are additional options for life-threatening PE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data from randomized clinical trials to guide treatment of DVT or PE in patients with acute ischemic stroke or ICH. The benefit of anticoagulation for the treatment of DVT or PE must be weighed against the risk of symptomatic hemorrhagic transformation in patients with ischemic stroke, and against the risk of hematoma expansion and rebleeding in patients with ICH.",
"   </p>",
"   <p>",
"    Embolectomy for patients with large central emboli is controversial but represents an option with a lower ICH risk than anticoagulation or thrombolysis in patients with life-threatening PE. The treatment of acute PE and massive PE is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of DVT and PE in patients with acute ICH is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DYSPHAGIA AND ASPIRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphagia related to stroke is more precisely characterized as oropharyngeal dysphagia, defined by swallowing impairment of the upper digestive tract. This definition has been extended to capture impairments in swallowing efficiency and safety, including delays in the timing of movements, reduced range of movements, and frank aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/29\">",
"     29",
"    </a>",
"    ]. Aspiration in this population is usually a sign of severe dysphagia, and refers to abnormal entry of fluid, particulate exogenous substances, or endogenous secretions into the airways.",
"   </p>",
"   <p>",
"    Dysphagia is very common after stroke and is a major risk factor for developing aspiration pneumonia. These observations are supported by a systematic review of 24 studies that evaluated oropharyngeal dysphagia and aspiration in adult patients with stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/29\">",
"     29",
"    </a>",
"    ]. In pooled analysis of the small number of studies with sufficient data, dysphagia was associated with a significantly increased risk of pneumonia compared with no dysphagia (relative risk (RR) 3.17, 95% CI 2.07-4.87), and aspiration was also associated with an increased pneumonia risk compared with no aspiration (RR 11.56, 95% CI 3.36-39.77).",
"   </p>",
"   <p>",
"    The incidence of dysphagia after stroke was lowest when identified by screening methods, mainly water swallow (37 to 45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/29\">",
"     29",
"    </a>",
"    ]. The incidence was intermediate when identified by a trained swallowing clinician (51 to 55 percent), and it was highest when identified by instrumental testing, mainly videofluoroscopy (64 to 78 percent). The dysphagia rates may have been overestimated by instrumental testing, which can reveal movement patterns that reflect the normal effects of aging; these were not distinguished from pathologic dysphagia by the definitions used in the studies.",
"   </p>",
"   <p>",
"    Independent predictors of dysphagia on initial presentation include male gender, age greater than 70, disabling stroke, impaired pharyngeal response, incomplete oral clearance, and palatal weakness or asymmetry [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bedside tests to screen for swallowing dysfunction are important but are not completely accurate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/31\">",
"     31",
"    </a>",
"    ]. One study found that the best bedside predictors of aspiration to thin liquid were spontaneous cough during test swallows and the overall sense of the presence of aspiration by the examiner [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/32\">",
"     32",
"    </a>",
"    ]. A 2012 systematic review found that cough or voice change in response to bedside water swallow test had a low to moderate sensitivity and moderate to high specificity for predicting aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to assess patients for their swallowing function prior to administering oral medications or food [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/8\">",
"     8",
"    </a>",
"    ], despite the lower sensitivity of screening tests compared with more comprehensive testing. In a prospective, multicenter study, use of a formal screening protocol for dysphagia (eg, water swallow test) for all patients admitted with stroke was associated with a significantly decreased risk of aspiration pneumonia compared with no formal screen (adjusted odds ratio 0.10, 95% CI 0.03-0.45) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/34\">",
"     34",
"    </a>",
"    ]. The pneumonia rates at sites with and without a formal dysphagia screen were 2.4 versus 5.4 percent, for an absolute risk reduction of 3 percent.",
"   </p>",
"   <p>",
"    Prevention of aspiration in patients with acute stroke includes initial nulla per os (NPO) status for those who may be at risk for aspiration and subsequent dietary modifications for those who have persistent dysphagia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=see_link\">",
"     \"Diagnosis and treatment of oropharyngeal dysphagia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PULMONARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary complications are very common after stroke. Among the most feared complications are pneumonia, neurogenic pulmonary edema, and the need for intubation and mechanical ventilation. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10087?source=see_link\">",
"     \"Stroke-related pulmonary complications and abnormal respiratory patterns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CARDIAC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiographic (ECG) changes often occur in the setting of stroke, likely mediated by the autonomic nervous system. Elevated cardiac enzymes, arrhythmias, myocardial infarction, and neurogenic cardiac injury are additional concomitants of acute stroke. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26952?source=see_link\">",
"     \"Cardiac complications of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GENITOURINARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infection (UTI) is a frequent medical complication after stroke, occurring in 11 to 15 percent of patients followed for up to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/1,4\">",
"     1,4",
"    </a>",
"    ], and it constitutes a serious medical complication in about 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/2\">",
"     2",
"    </a>",
"    ]. UTI remains a common complication when patients are followed for up to 30 months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is common practice to place indwelling bladder catheters in patients with stroke due to immobility, incontinence, urinary retention, or convenience. However, placement of an indwelling bladder catheter is an important risk factor for infection, and the duration of catheterization is directly related to risk of UTI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/35\">",
"     35",
"    </a>",
"    ]. Because of this risk, national guidelines recommend avoiding the use of indwelling urinary catheters whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with catheter related UTI are asymptomatic and do not have peripheral white blood cell counts different from other catheterized hospitalized patients without UTI. Urine cultures are therefore important in diagnosing catheter-related UTI After the diagnosis is made, treatment options should be tailored to the culture results and regional organism sensitivities.",
"   </p>",
"   <p>",
"    Bladder catheter management, methods to reduce the risk of infection associated with indwelling catheters, and treatment of catheter-associated UTI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to acute cystitis in women, acute cystitis in men, recurrent UTI, and acute pyelonephritis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15479?source=see_link\">",
"     \"Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5514?source=see_link\">",
"     \"Recurrent urinary tract infection in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Urologic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary incontinence is a common problem after stroke, occurring in 32 to 79 percent of patients on admission, and 25 to 28 percent at discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/36\">",
"     36",
"    </a>",
"    ]. The most common urodynamic finding is detrusor hyperreflexia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/37\">",
"     37",
"    </a>",
"    ]. The loss of inhibitory input from higher neurologic centers is thought to cause this hyperreflexia leading to urinary urgency, frequency, and urge incontinence. A prospective study of 60 patients found that detrusor hyperreflexia occurred in most patients with frontoparietal and internal capsule infarcts, while normal urodynamic studies were found in those with temporo-occipital lobe infarcts [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to detrusor hyperreflexia, detrusor hyporeflexia or areflexia may also occur following stroke, leading to overflow incontinence. In the prospective study cited above, detrusor areflexia within 72 hours of ischemic stroke symptom onset was reported in about 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/37\">",
"     37",
"    </a>",
"    ]. Bladder areflexia occurred with frontoparietal, internal capsule, basal ganglia, thalamic, pontine, and cerebellar infarcts. Bladder areflexia was also seen in 17 of 20 patients (85 percent) who had hemorrhagic infarction. Other factors contributing to urinary retention include the use of anticholinergic drugs, diabetic cystopathy, and bladder outlet obstruction.",
"   </p>",
"   <p>",
"    Detrusor-sphincter dyssynergia is an uncommon phenomenon in patients with recent stroke, unlike other neurologic disorders associated with incontinence.",
"   </p>",
"   <p>",
"    The type of urologic dysfunction has not been linked to stroke laterality. However, large infarcts (cortical plus subcortical area involvement) have been associated with an increased risk of incontinence in patients studied around 21 days post ischemic stroke, although this finding has not been consistent throughout studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of poststroke incontinence decreases with time. Of a group of 95 patients with incontinence 7 to 10 days after stroke, incontinence persisted at three months, one year, and two years in 34, 23, and 12 patients (36, 24, and 13 percent), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary incontinence is a poor prognostic sign after stroke, perhaps because it is a marker of stroke severity, as illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that assessed outcome one year after a first-ever stroke in patients younger than age 75 from southeast England, initial incontinence was the best single predictor of moderate to severe disability, with a sensitivity of 62 percent and specificity of 82 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of 935 consecutive patients with acute stroke from Denmark, mortality at six months among those who initially had complete, partial, or no urinary incontinence was 60, 25, and 7 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a community-based study from Australia of 370 patients with first-ever stroke, the presence of urinary incontinence among 30 day survivors predicted death over five years (hazard ratio 2.0; 95% CI 1. 3-3.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Norwegian study of 315 consecutive patients with first-ever or recurrent acute stroke, the presence of new-onset poststroke urinary incontinence with impaired awareness of bladder needs was associated with poor outcome (death or nursing home placement) at three months (odds ratio [OR] 27.5, 95% CI 7.0-108.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/44\">",
"       44",
"      </a>",
"      ]. However, new-onset urge urinary incontinence (with preserved awareness of bladder needs) was associated with a statistically nonsignificant trend towards poor outcome (OR 2.4, 95% CI 0.8-7.3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Practitioners can easily overlook urinary incontinence if patients or nursing staff are not directly queried. Diagnosis of the type of incontinence and appropriate treatment can be coordinated with a urologist. Detrusor hyperreflexia can be treated with scheduled voiding, tailored fluid restriction, and anticholinergic drugs. Indwelling bladder catheter placement should be avoided when possible to decrease the risks of nosocomial infection.",
"   </p>",
"   <p>",
"    The evaluation and treatment of urinary incontinence is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7192?source=see_link\">",
"     \"Epidemiology, risk factors, and pathogenesis of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sexual dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in sexual function after stroke may be related to multiple organic and psychosocial factors including fear of stroke recurrence, fear of impotence, medication effects, physical disability, sensory deficits, and cognitive deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/45\">",
"     45",
"    </a>",
"    ]. Moderate or complete dissatisfaction with sexual life after stroke occurs in 40 to 51 percent of patients compared with about 10 percent in the same patients before stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The most commonly cited aspect of sexual dysfunction in men is decreased libido followed by ejaculatory dysfunction and impotence. In women, decreased vaginal lubrication is somewhat more common than orgasmic failure.",
"   </p>",
"   <p>",
"    Incontinence in men should be treated before tackling treatment of sexual dysfunction. Evaluation for depression or hormonal deficiencies is indicated in those with decreased libido. Options for treatment of erectile dysfunction in the setting of stroke are not different from those associated with other etiologies; however, a cardiac evaluation and recognition of possible risks in patients with stroke should be considered before using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Treatment options for sexual dysfunction and impotence have widened with the development of pro-erectile oral medications. The treatment of male and female sexual dysfunction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link\">",
"     \"Sexual dysfunction in women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Gastrointestinal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rates of gastrointestinal (GI) hemorrhage associated with acute stroke are often not reported as part of medical complications, GI bleeding was one of the more common complications in the RANTTAS cohort, with serious and non-serious manifestations in 3 and 2 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/2\">",
"     2",
"    </a>",
"    ]. These statistics are in keeping with other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older patients, those with more significant impairment from the stroke, and those with more disability predating the incident stroke appear to be at higher risk for GI hemorrhage, while the use of antiplatelet and anticoagulation may not be related [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients with acute stroke and GI hemorrhage have higher mortality rates, but in most cases this does not appear to be directly related to the hemorrhage.",
"   </p>",
"   <p>",
"    GI prophylaxis has been advocated for patients who need intensive care unit (ICU) management due to a central nervous system process, but not as routine therapy for all patients with stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/50\">",
"     50",
"    </a>",
"    ]. However, given that patients not receiving enteral feeds are at higher risk for GI bleeding than those receiving feeds, the use of GI prophylaxis in patients with stroke who are nulla per os (NPO) may be reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/51\">",
"     51",
"    </a>",
"    ]. Withholding of antiplatelet or anticoagulant therapy in the setting of GI bleeding should be individualized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional status on admission after stroke may be associated with mortality and functional outcome. This observation comes from a preliminary study of 3012 patients hospitalized with a recent stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/52\">",
"     52",
"    </a>",
"    ]. Undernourished patients had significantly higher mortality at six months compared with patients who were normally nourished (odds ratio 1.82, 95% CI 1.34-2.47 after adjustment for age, prestroke functional state, and stroke severity), and they were more likely to develop pneumonia, other infections, and GI bleeding during their hospital admission. Thus, assessment of nutritional status at the time of admission and corrective measures for undernourished patients seem reasonable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=see_link\">",
"     \"Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=see_link\">",
"     \"Enteral feeding: Gastric versus post-pyloric\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In agreement with current guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/8,53\">",
"     8,53",
"    </a>",
"    ], we suggest that patients with acute stroke who cannot take food and fluids orally should receive nutrition and hydration via nasogastric, nasoduodenal, or PEG feedings while undergoing efforts to restore swallowing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     FALLS AND BONE FRACTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Falls have been cited as the one of the most common complications of acute stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/1\">",
"     1",
"    </a>",
"    ]. In a prospective multicenter study of 311 patients followed up to 30 months after stroke, falls occurred in 25 percent and were associated with serious injury in 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/1\">",
"     1",
"    </a>",
"    ]. Hip fractures represent 45 percent of poststroke fractures and are two to four times more common in the population with stroke compared with an age-matched reference population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hospitalized patients with stroke not only have skeletal \"unloading\" secondary to bed rest, but they also have disuse of the paretic limbs. These factors predispose patients to bone resorption. Patients who are able to ambulate early after stroke appear to lose bone density only on the paretic side (hemiosteoporosis), while those who are not ambulatory lose bone mineral density on both sides. Relearning to walk by two months has been associated with diminished bone density loss compared with remaining wheelchair bound [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most fractures after stroke occur on the paretic side and are secondary to accidental falls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/54,56\">",
"     54,56",
"    </a>",
"    ]. Patients tend to fall toward the paretic side and without ample protective responses, such as outstretching an arm, these patients are at higher risk for fractures. Both lower bone mineral density and ipsilateral triceps weakness are associated with higher risk of post-fall fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direction of the fall also helps determine fracture risk. Falls forward are associated with decreased wrist fractures, while falls backward are associated with an increased risk of wrist fractures, but a decreased rate of hip fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/57\">",
"     57",
"    </a>",
"    ]. As would be expected, outstretching an arm during the fall increases the risk of wrist fractures and decreases the risk of hip fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fall precautions should be considered in all patients with stroke; those with cognitive impairment, neglect, and anosognosia may be at especially high risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of hip fractures may be increased in the setting of serum 25-hydroxyvitamin D deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/58\">",
"     58",
"    </a>",
"    ]. One small clinical trial found that supplementation with ergocalciferol (vitamin D2) 1,000 international units daily reduced the risk of falls and hip fractures in patients with longstanding stroke, all of whom had low baseline serum 25-hydroxyvitamin D levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/59\">",
"     59",
"    </a>",
"    ]. This trial was the only 1 of 13 identified by a systematic review of randomized trials evaluating fall prevention after stroke to show a beneficial effect of any treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/60\">",
"     60",
"    </a>",
"    ]. Other interventions (sunlight exposure, oral bisphosphonate, physical activity training, environmental modification, patient education, home rehabilitation) were no better than usual care. The methodologic quality of the included trials was variable, and most were not blinded. It is unknown whether vitamin D supplementation is beneficial for patients with acute stroke.",
"   </p>",
"   <p>",
"    Randomized clinical trials have found that oral bisphosphonate therapy is associated with a reduced risk of hip fractures in women with mild acute stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/61\">",
"     61",
"    </a>",
"    ], and in men with chronic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/62\">",
"     62",
"    </a>",
"    ]. However, the utility of oral bisphosphonates is limited by high rates of dysphagia in patients with acute stroke. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Dysphagia and aspiration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    No trials have evaluated intravenous bisphosphonate therapy for preventing hip fracture after acute stroke, but a randomized trial involving 27 patients with acute hemiplegic stroke found that a single infusion of zoledronate prevented bone loss at the hemiplegic hip [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate diagnostic x-rays should be obtained in patients who fall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poststroke depression is common, although difficult to quantify precisely due to methodologic differences among studies. In a 2013 meta-analysis, with pooled data from 43 studies and over 20,000 patients, the prevalence of depression observed at any time after stroke was 29 percent (95% CI 25-32 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/64\">",
"     64",
"    </a>",
"    ]. There was no significant difference in prevalence rates of depression at different time points after stroke. In pooled data from 10 studies with over 16,000 patients, predictors of poststroke depression were disability, prestroke depression, cognitive impairment, stroke severity, and anxiety.",
"   </p>",
"   <p>",
"    The theory that depression is more commonly associated with left than with right hemisphere strokes and with lesions of the left anterior brain than with other regions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/65\">",
"     65",
"    </a>",
"    ] is not supported by the data. In a systematic review of 48 studies, the relative risk of depression after a left versus right hemisphere stroke was 0.95 (95% CI 0.83-1.10) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/66\">",
"     66",
"    </a>",
"    ]. Similarly, the risk of depression after a left anterior lesion compared with all other brain lesions was 1.17 (0.87-1.62). Restriction of the analyses to reports from high-quality studies or major depressive disorder did not substantially change the results.",
"   </p>",
"   <p>",
"    Depression at three months after stroke is correlated with a poor outcome at one year, although causation cannot be inferred from this [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/67\">",
"     67",
"    </a>",
"    ]. Nonetheless, when patients are matched for initial functional outcome, remission of depression is associated with a better functional outcome at three and six months than continued depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/68\">",
"     68",
"    </a>",
"    ]. There appears to be a relationship between depression and 12 and 24 months mortality, but confounders likely exist [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are many depression scales that can be used to assess depression after stroke. The single question \"Do you often feel sad or depressed?\" was found to have a sensitivity and specificity of 86 and 78 percent, respectively when used against the Montgomery-Asberg depression rating in screening for poststroke depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of pharmacotherapy, psychotherapy, or combined use of these modalities for poststroke depression is not established, but accumulating evidence suggests that these interventions are beneficial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2008 systematic review of 12 pharmacotherapy trials with 1121 subjects found that antidepressant therapy is modestly beneficial for remission of poststroke depression (pooled odds ratio 0.47, 95% CI 0.22-0.98) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/71\">",
"       71",
"      </a>",
"      ]. However, adverse events were significantly more common with antidepressants. In three trials testing psychotherapy with 445 subjects, there was no evidence of benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A controlled trial (not included in the systematic review) of 188 patients with poststroke depression found that a care management program, which included depression education, antidepressant treatment guided by algorithm, and monitoring of therapy, was more effective than usual care (which included discretionary use of antidepressants) for improving depression at 12 weeks after treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another trial of 101 patients with severe depression within four months of ischemic stroke, an eight-week psychosocial&ndash;behavioral intervention plus antidepressant therapy was superior to antidepressant treatment alone for reduction in depressive symptom severity at 12 months after study entry [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no definitive evidence to guide the specific choice of therapy for patients with poststroke depression. However, major depression is a treatable illness that responds to a variety of therapeutic interventions, and it is likely that the standard approach to the treatment of depression in adults is generalizable to patients with poststroke depression. The initial treatment of depression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is some evidence that treatment of depression after stroke may positively affect functional outcome and perhaps cognitive function. However, the benefit is not robust in all studies, and it often does not meet statistical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/74-79\">",
"     74-79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether interventions to prevent poststroke depression are warranted.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2008 systematic review identified 14 trials involving 1515 subjects that evaluated prevention of poststroke depression [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/80\">",
"       80",
"      </a>",
"      ]. In 10 trials of pharmacological therapy, there was no clear benefit. In four trials testing psychotherapy, there was a statistically significant benefit for prevention of depression, but the treatment effects were small",
"     </li>",
"     <li>",
"      In a later controlled trial of 176 patients without depression who were within three months of acute stroke,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      was superior to placebo over 12 months of treatment for the prevention of poststroke depression [",
"      <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study in rigorous clinical trials is needed to determine the utility of antidepressant interventions after acute stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/45/3795?source=see_link\">",
"       \"Patient information: Recovery after stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical complications are common and influence outcome after ischemic stroke. The most common serious medical complications include pneumonia, gastrointestinal (GI) bleeding, congestive heart failure, cardiac arrest, deep vein thrombosis (DVT), pulmonary embolism (PE), and urinary tract infection (UTI) (",
"    <a class=\"graphic graphic_table graphicRef68148 \" href=\"UTD.htm?10/49/11036\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our recommendations are based upon clinical experience, practice guidelines published by the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/23\">",
"     23",
"    </a>",
"    ], the American College of Physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/25\">",
"     25",
"    </a>",
"    ], the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/8\">",
"     8",
"    </a>",
"    ], the National Institute for Health and Clinical Excellence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/12/17610/abstract/53\">",
"     53",
"    </a>",
"    ], and clinical data published after the guidelines.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hemiparesis, immobility, severe stroke, and advanced age are predisposed to DVT development. Pulmonary embolism (PE) accounts for 13 to 25 percent of early deaths after stroke.",
"     </li>",
"     <li>",
"      For patients with acute stroke who have restricted mobility, we suggest venous thromboembolism (VTE) prophylaxis with early low-dose anticoagulant therapy using either low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (LMWH) or unfractionated heparin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This recommendation applies only to patients for whom the assessed benefit of VTE prophylaxis is thought to outweigh the risk of bleeding. Reasonable regimens include subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      40 mg once daily or subcutaneous heparin 5000 units two times to three times daily. In combination with antithrombotic prophylaxis for patients with acute stroke and restricted mobility, we suggest the use of intermittent pneumatic compression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Anticoagulants should not be used for 24 hours after the administration of thrombolytic therapy. We recommend",
"      <strong>",
"       not",
"      </strong>",
"      using graduated compression stockings for VTE prophylaxis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). &nbsp;(See",
"      <a class=\"local\" href=\"#H3\">",
"       'Venous thromboembolism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'VTE prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VTE prophylaxis for patients with acute (or prior) intracerebral hemorrhage (ICH) is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=see_link&amp;anchor=H5#H5\">",
"       \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\", section on 'Prevention of VTE'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of proximal DVT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PE in patients with acute ischemic stroke may require initial use of unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin (LMWH) followed by oral anticoagulation, or placement of an inferior vena cava (IVC) filter. This issue is discussed separately. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'VTE treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"       \"Treatment of lower extremity deep vein thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment options for life-threatening PE include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , LMWH, embolectomy, and thrombolysis. Their effectiveness in patients with acute ischemic stroke is unknown. Choice of therapy will depend on individual patient factors and medical center expertise. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'VTE treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"       \"Treatment of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumonia is the most common cause of fever within the first 48 hours of acute stroke, and it is the most common medical complication two to four weeks after a supratentorial ischemic infarction. Aspiration is the cause of about two-thirds of poststroke pneumonia, and it is usually due to stroke-related dysphagia or to decreased level of consciousness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10087?source=see_link&amp;anchor=H2#H2\">",
"       \"Stroke-related pulmonary complications and abnormal respiratory patterns\", section on 'Pneumonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend assessment of swallowing function for all patients admitted with acute stroke prior to administering oral medications or food (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest use of a formal screening protocol for dysphagia for all patients admitted with stroke (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Prevention of aspiration in patients with dysphagia includes initial nulla per os (NPO) status for those who may be at risk for aspiration and subsequent dietary modifications for those who have persistent dysphagia. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Dysphagia and aspiration'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=see_link\">",
"       \"Diagnosis and treatment of oropharyngeal dysphagia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with acute stroke who cannot take food and fluids orally, we suggest maintaining nutrition and hydration via nasogastric, nasoduodenal, or PEG feedings (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angina, myocardial infarction, and cardiac ischemia complicate 6 percent of acute strokes and constitute serious or life-threatening medical events in 1 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26952?source=see_link\">",
"       \"Cardiac complications of stroke\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"       \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      UTI is a frequent medical complication after stroke and constitutes a serious medical complication in about 1 percent. Placement of an indwelling bladder catheter is an important risk factor for infection. Because of this risk, the use of indwelling urinary catheters should be avoided whenever possible. Urinary incontinence is a common problem after stroke, often associated with detrusor hyperreflexia. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Urinary tract infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Urologic dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Changes in sexual function after stroke may be related to multiple organic and psychosocial factors including fear of stroke recurrence, fear of impotence, medication effects, and neurologic impairments. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Sexual dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GI bleeding is one of the more common complications of acute stroke. Older age, stroke severity, and prior disability appear to increase risk for GI hemorrhage. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Gastrointestinal bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest assessment of baseline nutritional status and measures to correct any major nutritional problems in patients with acute ischemic stroke (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Nutrition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=see_link\">",
"       \"Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=see_link\">",
"       \"Enteral feeding: Gastric versus post-pyloric\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Falls are very common after acute stroke and are associated with serious injury in 5 percent of patients. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Falls and bone fractures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of poststroke depression is 18 to 61 percent. Stroke severity, physical disability, and cognitive impairment are likely risk factors. The effectiveness of pharmacotherapy, psychotherapy, or combined use of these modalities for poststroke depression is not established, but accumulating evidence suggests that these interventions are beneficial. Thus, the standard approach to the treatment of depression is likely to be generalizable to patients with poststroke depression. The initial treatment of depression is discussed separately. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Depression'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/1\">",
"      Langhorne P, Stott DJ, Robertson L, et al. Medical complications after stroke: a multicenter study. Stroke 2000; 31:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/2\">",
"      Johnston KC, Li JY, Lyden PD, et al. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. Stroke 1998; 29:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/3\">",
"      Indredavik B, Rohweder G, Naalsund E, Lydersen S. Medical complications in a comprehensive stroke unit and an early supported discharge service. Stroke 2008; 39:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/4\">",
"      Ingeman A, Andersen G, Hundborg HH, et al. In-hospital medical complications, length of stay, and mortality among stroke unit patients. Stroke 2011; 42:3214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/5\">",
"      Silver FL, Norris JW, Lewis AJ, Hachinski VC. Early mortality following stroke: a prospective review. Stroke 1984; 15:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/6\">",
"      Viitanen M, Winblad B, Asplund K. Autopsy-verified causes of death after stroke. Acta Med Scand 1987; 222:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/7\">",
"      Bae HJ, Yoon DS, Lee J, et al. In-hospital medical complications and long-term mortality after ischemic stroke. Stroke 2005; 36:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/8\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2013; 44:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/9\">",
"      Kamran SI, Downey D, Ruff RL. Pneumatic sequential compression reduces the risk of deep vein thrombosis in stroke patients. Neurology 1998; 50:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/10\">",
"      Davenport RJ, Dennis MS, Wellwood I, Warlow CP. Complications after acute stroke. Stroke 1996; 27:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/11\">",
"      The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/12\">",
"      Kelly J, Rudd A, Lewis RR, et al. Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. Stroke 2004; 35:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/13\">",
"      Dennis M, Mordi N, Graham C, et al. The timing, extent, progression and regression of deep vein thrombosis in immobile stroke patients: observational data from the CLOTS multicenter randomized trials. J Thromb Haemost 2011; 9:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/14\">",
"      Kelly J, Rudd A, Lewis R, Hunt BJ. Venous thromboembolism after acute stroke. Stroke 2001; 32:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/15\">",
"      Landi G, D'Angelo A, Boccardi E, et al. Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability. Arch Neurol 1992; 49:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/16\">",
"      Warlow C, Ogston D, Douglas AS. Deep venous thrombosis of the legs after strokes. Part I--incidence and predisposing factors. Br Med J 1976; 1:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/17\">",
"      Wijdicks EF, Scott JP. Pulmonary embolism associated with acute stroke. Mayo Clin Proc 1997; 72:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/18\">",
"      Bath PM, Iddenden R, Bath FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke : a meta-analysis of randomized controlled trials. Stroke 2000; 31:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/19\">",
"      Sandercock PA, Counsell C, Tseng MC. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev 2008; :CD000119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/20\">",
"      Kamphuisen PW, Agnelli G. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke? Thromb Res 2007; 119:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/21\">",
"      Shorr AF, Jackson WL, Sherner JH, Moores LK. Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis. Chest 2008; 133:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/22\">",
"      Sherman DG, Albers GW, Bladin C, et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 2007; 369:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/23\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/24\">",
"      Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e227S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/25\">",
"      Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2011; 155:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/26\">",
"      CLOTS Trials Collaboration, Dennis M, Sandercock PA, et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet 2009; 373:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/27\">",
"      Qaseem A, Chou R, Humphrey LL, et al. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011; 155:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/28\">",
"      Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost 2005; 3:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/29\">",
"      Martino R, Foley N, Bhogal S, et al. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke 2005; 36:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/30\">",
"      Mann G, Hankey GJ. Initial clinical and demographic predictors of swallowing impairment following acute stroke. Dysphagia 2001; 16:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/31\">",
"      Schepp SK, Tirschwell DL, Miller RM, Longstreth WT Jr. Swallowing screens after acute stroke: a systematic review. Stroke 2012; 43:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/32\">",
"      McCullough GH, Wertz RT, Rosenbek JC. Sensitivity and specificity of clinical/bedside examination signs for detecting aspiration in adults subsequent to stroke. J Commun Disord 2001; 34:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/33\">",
"      Daniels SK, Anderson JA, Willson PC. Valid items for screening dysphagia risk in patients with stroke: a systematic review. Stroke 2012; 43:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/34\">",
"      Hinchey JA, Shephard T, Furie K, et al. Formal dysphagia screening protocols prevent pneumonia. Stroke 2005; 36:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/35\">",
"      Sedor J, Mulholland SG. Hospital-acquired urinary tract infections associated with the indwelling catheter. Urol Clin North Am 1999; 26:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/36\">",
"      Brittain KR, Peet SM, Castleden CM. Stroke and incontinence. Stroke 1998; 29:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/37\">",
"      Burney TL, Senapati M, Desai S, et al. Acute cerebrovascular accident and lower urinary tract dysfunction: a prospective correlation of the site of brain injury with urodynamic findings. J Urol 1996; 156:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/38\">",
"      Gelber DA, Good DC, Laven LJ, Verhulst SJ. Causes of urinary incontinence after acute hemispheric stroke. Stroke 1993; 24:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/39\">",
"      Reding, MJ, Winter, SW, Hochrein, SA, et al. Urinary incontinence after unilateral hemispheric stroke: A neurologic-epidemiologic perspective. J Neurol Rehabil 1987; 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/40\">",
"      Patel M, Coshall C, Rudd AG, Wolfe CD. Natural history and effects on 2-year outcomes of urinary incontinence after stroke. Stroke 2001; 32:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/41\">",
"      Taub NA, Wolfe CD, Richardson E, Burney PG. Predicting the disability of first-time stroke sufferers at 1 year. 12-month follow-up of a population-based cohort in southeast England. Stroke 1994; 25:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/42\">",
"      Nakayama H, J&oslash;rgensen HS, Pedersen PM, et al. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. Stroke 1997; 28:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/43\">",
"      Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 2000; 31:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/44\">",
"      Pettersen R, Wyller TB. Prognostic significance of micturition disturbances after acute stroke. J Am Geriatr Soc 2006; 54:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/45\">",
"      Marinkovic SP, Badlani G. Voiding and sexual dysfunction after cerebrovascular accidents. J Urol 2001; 165:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/46\">",
"      Korpelainen JT, Kauhanen ML, Kemola H, et al. Sexual dysfunction in stroke patients. Acta Neurol Scand 1998; 98:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/47\">",
"      Korpelainen JT, Nieminen P, Myllyl&auml; VV. Sexual functioning among stroke patients and their spouses. Stroke 1999; 30:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/48\">",
"      Davenport RJ, Dennis MS, Warlow CP. Gastrointestinal hemorrhage after acute stroke. Stroke 1996; 27:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/49\">",
"      O'Donnell MJ, Kapral MK, Fang J, et al. Gastrointestinal bleeding after acute ischemic stroke. Neurology 2008; 71:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/50\">",
"      Navab F, Steingrub J. Stress ulcer: is routine prophylaxis necessary? Am J Gastroenterol 1995; 90:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/51\">",
"      Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med 1999; 27:2812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/52\">",
"      FOOD Trial Collaboration. Poor nutritional status on admission predicts poor outcomes after stroke: observational data from the FOOD trial. Stroke 2003; 34:1450.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Stroke: The diagnosis and acute management of stroke and transient ischaemic attacks. Royal College of Physicians, London 2008. file://www.nice.org.uk/CG068 (Accessed on February 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/54\">",
"      Ramnemark A, Nyberg L, Borss&eacute;n B, et al. Fractures after stroke. Osteoporos Int 1998; 8:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/55\">",
"      J&oslash;rgensen L, Jacobsen BK, Wilsgaard T, Magnus JH. Walking after stroke: does it matter? Changes in bone mineral density within the first 12 months after stroke. A longitudinal study. Osteoporos Int 2000; 11:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/56\">",
"      Myint PK, Poole KE, Warburton EA. Hip fractures after stroke and their prevention. QJM 2007; 100:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/57\">",
"      Nevitt MC, Cummings SR. Type of fall and risk of hip and wrist fractures: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 1993; 41:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/58\">",
"      Sato Y, Asoh T, Kondo I, Satoh K. Vitamin D deficiency and risk of hip fractures among disabled elderly stroke patients. Stroke 2001; 32:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/59\">",
"      Sato Y, Iwamoto J, Kanoko T, Satoh K. Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. Cerebrovasc Dis 2005; 20:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/60\">",
"      Batchelor F, Hill K, Mackintosh S, Said C. What works in falls prevention after stroke?: a systematic review and meta-analysis. Stroke 2010; 41:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/61\">",
"      Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005; 64:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/62\">",
"      Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005; 165:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/63\">",
"      Poole KE, Loveridge N, Rose CM, et al. A single infusion of zoledronate prevents bone loss after stroke. Stroke 2007; 38:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/64\">",
"      Ayerbe L, Ayis S, Wolfe CD, Rudd AG. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry 2013; 202:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/65\">",
"      Robinson RG, Price TR. Post-stroke depressive disorders: a follow-up study of 103 patients. Stroke 1982; 13:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/66\">",
"      Carson AJ, MacHale S, Allen K, et al. Depression after stroke and lesion location: a systematic review. Lancet 2000; 356:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/67\">",
"      Herrmann N, Black SE, Lawrence J, et al. The Sunnybrook Stroke Study: a prospective study of depressive symptoms and functional outcome. Stroke 1998; 29:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/68\">",
"      Chemerinski E, Robinson RG, Kosier JT. Improved recovery in activities of daily living associated with remission of poststroke depression. Stroke 2001; 32:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/69\">",
"      House A, Knapp P, Bamford J, Vail A. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke 2001; 32:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/70\">",
"      Watkins C, Daniels L, Jack C, et al. Accuracy of a single question in screening for depression in a cohort of patients after stroke: comparative study. BMJ 2001; 323:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/71\">",
"      Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database Syst Rev 2008; :CD003437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/72\">",
"      Williams LS, Kroenke K, Bakas T, et al. Care management of poststroke depression: a randomized, controlled trial. Stroke 2007; 38:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/73\">",
"      Mitchell PH, Veith RC, Becker KJ, et al. Brief psychosocial-behavioral intervention with antidepressant reduces poststroke depression significantly more than usual care with antidepressant: living well with stroke: randomized, controlled trial. Stroke 2009; 40:3073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/74\">",
"      Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000; 31:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/75\">",
"      Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000; 157:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/76\">",
"      Kimura M, Robinson RG, Kosier JT. Treatment of cognitive impairment after poststroke depression : a double-blind treatment trial. Stroke 2000; 31:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/77\">",
"      Gainotti G, Antonucci G, Marra C, Paolucci S. Relation between depression after stroke, antidepressant therapy, and functional recovery. J Neurol Neurosurg Psychiatry 2001; 71:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/78\">",
"      Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry 2003; 160:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/79\">",
"      Schmid AA, Kroenke K, Hendrie HC, et al. Poststroke depression and treatment effects on functional outcomes. Neurology 2011; 76:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/80\">",
"      Hackett ML, Anderson CS, House A, Halteh C. Interventions for preventing depression after stroke. Cochrane Database Syst Rev 2008; :CD003689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/12/17610/abstract/81\">",
"      Robinson RG, Jorge RE, Moser DJ, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 2008; 299:2391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1093 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17610=[""].join("\n");
var outline_f17_12_17610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VENOUS THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VTE prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90846593\">",
"      - Intermittent pneumatic compression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90846716\">",
"      - Aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90846504\">",
"      - Graduated compression stockings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Conclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      VTE treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DYSPHAGIA AND ASPIRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PULMONARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CARDIAC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GENITOURINARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Urologic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      GASTROINTESTINAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FALLS AND BONE FRACTURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1093\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1093|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/49/21275\" title=\"table 1\">",
"      Common medical complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/49/11036\" title=\"table 2\">",
"      Serious medical complications of stroke",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15479?source=related_link\">",
"      Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26952?source=related_link\">",
"      Cardiac complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=related_link\">",
"      Diagnosis and treatment of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=related_link\">",
"      Enteral feeding: Gastric versus post-pyloric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7192?source=related_link\">",
"      Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/45/3795?source=related_link\">",
"      Patient information: Recovery after stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=related_link\">",
"      Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5514?source=related_link\">",
"      Recurrent urinary tract infection in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10087?source=related_link\">",
"      Stroke-related pulmonary complications and abnormal respiratory patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_12_17611="Heart in hyperthyroidism";
var content_f17_12_17611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cardiovascular effects of hyperthyroidism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Finding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart rate",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary artery pressure",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic vascular resistance",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac output",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ejection fraction",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diastolic relaxation",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diastolic blood pressure",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial oxygen consumption",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anginal syndrome",
"       </td>",
"       <td>",
"        Can induce or worsen",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17611=[""].join("\n");
var outline_f17_12_17611=null;
var title_f17_12_17612="Thoracic inlet obstruction";
var content_f17_12_17612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Variable obstruction at the thoracic inlet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 168px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow volume loop in variable obstruction at the thoracic inlet showing a double hump in the the expiratory curve as the narrowing moves from an intrathoracic to a relative extrathoracic location toward the end of expiration",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17612=[""].join("\n");
var outline_f17_12_17612=null;
var title_f17_12_17613="History skin lesions after OLT";
var content_f17_12_17613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evolution of skin lesions after liver transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Dermatologic condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Liver disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Evolution after liver transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acanthosis nigricans",
"       </td>",
"       <td>",
"        Primary biliary cirrhosis",
"       </td>",
"       <td>",
"        Improvement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alopecia areata",
"       </td>",
"       <td>",
"        Autoimmune hepatitis",
"       </td>",
"       <td>",
"        Most frequently improvement in the 4 to 12 weeks following transplantation. Occasionally, new alopecia spots appear with immunosuppression.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure alopecia",
"       </td>",
"       <td>",
"        Living donor",
"       </td>",
"       <td>",
"        Reported in living donors [1,2].",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azure lunules (blue discoloration of the bases of the fingernails)",
"       </td>",
"       <td>",
"        Wilson's disease",
"       </td>",
"       <td>",
"        Discoloration disappears as the metabolic defect is corrected.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lichen planus",
"       </td>",
"       <td>",
"        <p>",
"         Viral hepatitis B and C",
"        </p>",
"        <p>",
"         Primary biliary cirrhosis",
"        </p>",
"       </td>",
"       <td>",
"        Improves after liver transplantation. Chronic graft-versus-host-disease and parakeratosis occurring after liver transplantation may have a lichenoid appearance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Livedo reticularis",
"       </td>",
"       <td>",
"        Primary hyperoxaluria",
"       </td>",
"       <td>",
"        Improvement; Livedo reticularis can appear months after transplantation [3].",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Panniculitis",
"       </td>",
"       <td>",
"        Alpha 1-antitrypsin deficiency",
"       </td>",
"       <td>",
"        Improvement; Panniculitis has been reported to occur in a patient who acquired a PiZZ phenotype and resolve after transplantation [4].",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Photosensitivity",
"       </td>",
"       <td>",
"        Erythropoietic protoporphyria",
"       </td>",
"       <td>",
"        Improvement, but it may take months or even years. Recurrence has been described [5]. Intraoperative protection from phototoxic injury with a filter omitting wavelengths below 470 nm is recommended during liver transplantation [6].",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis",
"       </td>",
"       <td>",
"        Hepatitis C with cryoglobulinemia",
"       </td>",
"       <td>",
"        May worsen after transplantation as the viremia increases. Antiviral therapy may be beneficial [7].",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raynaud's phenomenon",
"       </td>",
"       <td>",
"        Primary biliary cirrhosis",
"       </td>",
"       <td>",
"        Improvement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitiligo",
"       </td>",
"       <td>",
"        Autoimmune hepatitis",
"       </td>",
"       <td>",
"        Improvement; Vitiligo occurring after transplantation due to the destruction of melanocytes by donor-derived immune reaction has been reported [8].",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Xanthomas Xanthelasmas",
"       </td>",
"       <td>",
"        Chronic cholestatic diseases, such as primary biliary cirrhosis, Alagille syndrome, familial hypercholesterolemia",
"       </td>",
"       <td>",
"        Improvement [9].",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Tomioka T, Hayashida M, Hanaoka K. Pressure alopecia in living donors for liver transplantation. Can J Anaesth 2004; 51:186.",
"     <br>",
"      2. Khalaf H, Negmi H, Hassan G, Al-Sebayel M. Postoperative alopecia areata: is pressure-induced ischemia the only cause to blame? Transplant Proc 2004; 36:2158.",
"      <br>",
"       3. Rubenstein MC, Martinelli PT, Bayer-Garner IB, et al. Persistent cutaneous manifestations of hyperoxaluria after combined hepatorenal transplantation. Dermatol Online J 2004; 10:10.",
"       <br>",
"        4. Fernandez-Torres R, Garcia-Silva J, Robles O, et al. Alfa-1-antitrypsin deficiency panniculitis acquired after liver transplant and successfully treated with retransplant. J Am Acad Dermatol 2009; 60:715.",
"        <br>",
"         5. Dowman JK, gunson BK, Mirza DF, et al. UK experience of liver transplantation for erythropoietic protoporphyria. J Inherit Metab Dis 2011; 34:539.",
"         <br>",
"          6. Wahlin S, Srikanthan N, Hamre B, et al. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. Liver Transpl 2008; 14:1340.",
"          <br>",
"           7. Francesca Donata M, Banfi G, Cresseri D, et al. Antiviral therapy of symptomatic HCV-mixed ���������cryoglobulinemia after liver transplant: Case ���������report and literature review. Int J Artif Organs. 2013 Feb 28 [Epub ahead of print].",
"           <br>",
"            8. Bradle V, Kemp EH, Dickinson C, et al. Vitiligo following a combined liver-kidney transplant. Nephrol Dial Transplant 2009; 24:686.",
"            <br>",
"             9. Maiorana A, Nobil V, Calandra S, et al. Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatr Transplant 2011; 15:E25.",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17613=[""].join("\n");
var outline_f17_12_17613=null;
var title_f17_12_17614="Prevalence of HTN in men";
var content_f17_12_17614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Prevalence of hypertension in men in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 257px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prevalence of hypertension in men according to age and race/ethnicity in the United States from the NHANES-III survey. Hypertension occurs earlier and more frequently in African-American men.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Burt, VL, Whelton, P, Roccella, EJ, et al, Hypertension 1995; 25:305.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17614=[""].join("\n");
var outline_f17_12_17614=null;
var title_f17_12_17615="Estrogen and tamoxifen binding";
var content_f17_12_17615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Simple model of estrogen (E) and tamoxifen (T) binding to the ligand binding domain of the estrogen receptor (ER)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 313px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Basic model in which ligand (estrogen or tamoxifen) displaces heat shock protein (HSP), resulting in binding of ligand-receptor complex to estrogen receptor element (ERE) of gene promoter region. ER binding directly to the ERE is one mechanism, but ER can also instead tether DNA binding transcription factors for modulate genes without a classical ERE.",
"    <div class=\"footnotes\">",
"     Arrow: gene activation; circle: gene repression.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: Diseases of the Breast, 2nd ed, Harris JR (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2000. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_12_17615=[""].join("\n");
var outline_f17_12_17615=null;
